Note: Descriptions are shown in the official language in which they were submitted.
CA 02582096 2012-02-02
CONVENIENTLY IMPLANTABLE SUSTAINED RELEASE DRUG COMPOSITIONS
HELD OF THE INVENTION
This invention provides for biocompatible and biodegradable syringeable
liquid,
implantable solid, and injectable gel pharmaceutical formulations useful for
the treatment of
systemic and local diseases.
BACKGROUND OF THE INVENTION
Present modes of drug delivery such as topical application, oral delivery, and
intramuscular, intravenous and subcutaneous injection may result in high and
low blood
concentrations and/or shortened half-life in the blood. In some cases,
achieving therapeutic
efficacy with these standard administrations requires large doses of
medications that may
result in toxic side effects. The technologies relating to controlled drug
release have been
attempted in an effort to circumvent some of the pitfalls of conventional
therapy. Their aims
are to deliver medications on a continuous and sustained manner. Additionally,
local control
drug release applications are site or organ specific.
In response to these issues, reservoir delivery systems have been explored.
Non-
biodegradable drug delivery systems include, for example, Vitrasert (Bausch &
Lomb), a
surgical-implant that delivers ganciclovir intraocularly; Duros (Durect
Corp.), surgically
implanted osmotic pump that delivers leuprolide actetate to treat advanced
prostate cancer,
and Implanon (Organon International), a type of subdermal contraceptive
implant.
Biodegradable implants include, for example, Lupron Depot (TAP Pharmaceutical
Prods., Inc.), a sustained-release microcapsule injection of luteinizing
hormone-releasing
hormone (LH-RH) analog for the treatment of prostate cancer; the Surodexo
dexamethasone
anterior segment drug delivery system (Oculex Pharmaceuticals, Inc.); and
Nutropin Depto
1
CA 02582096 2012-02-02
(Genentech), micronized particles of recombinant human growth hormone embedded
in
polylactide-coglycolide (PLG) microspheres.
Additionally, polyethylene glycol conjugations (pegylation) to reduce the
frequency
of administration are now in use. One example, pending FDA licensure, is
MacugenTM
(Eyetech Pharmaceuticals, Inc.), a pegylated anti-VEGF aptamer, for use in
treating wet
macular degeneration.
There remains a need for a more economical, practical, and efficient way of
producing and manufacturing drug delivery systems that could be used locally
or
systemically, in solid, semi-solid, or liquid formulations.
SUMMARY OF THE INVENTION
An object of the present invention provides for economical, practical, and
efficient
drug delivery system. According to the present invention, this drug delivery
system is
produced easily, delivered easily to the site of indication, and is both
biocompatible and
biodegradable. More specifically, the formulations of the present invention
provide for novel
therapies that are easily manipulated and injected or implanted by qualified
medical
practitioners. The formulations deliver therapeutic and non-toxic levels of
active agents over
the desired extended time frame, primarily at the site of implantation. The
formulations are
both biocompatible and biodegradable, and disappear harmlessly after
delivering active agent
to the desired site.
One embodiment of the present invention provides for a pharmaceutical
formulation
for implantation into a patient for the sustained release of an active agent
comprising a
biocompatible, biodegradable excipient and an active agent or pharmaceutically
acceptable
salt thereof. In an aspect of the invention, the formulation is capable of
being implanted
by injection.
Another embodiment of the invention provides for a pharmaceutical formulation
for
implantation into a patient for the sustained release of an active agent
comprising a
biocompatible, biodegradable excipient and an active agent or pharmaceutically
acceptable
salt thereof, wherein said formulation exhibits an in vitro dissolution
profile wherein about
2% to about 100% of the active agent is released over a period ranging from
about 1 day to at
least 365 days.
2
CA 02582096 2012-12-06
There is provided herein a pharmaceutical foimulation for the sustained
release of
one or more active agents consisting of at least one biocompatible,
biodegradable
excipient at a concentration of about 30% to about 99.9%; wherein said
biocompatible,
biodegradable excipient is selected from the group consisting of tocopherols
isomers and
tocotrienol isomers and their esters; benzyl benzoate; dimethyl sulfone;
triethyl, tripropyl,
and tributyl esters of 0-acetylcitrate; triethyl, tripropyl, tributyl esters
of citric acid and
mono, di, and tri esters of 0-acetylcitric acid with C1 to C10 straight and
branched chain
aliphatic alcohols; wherein said active agent is selected from the group
consisting of
analgesics, anesthetics, narcotics, angiostatic steroids, anti-inflammatory
steroids,
angiogenesis inhibitors, nonsteroidal anti-inflammatories, anti-infective
agents, anti-
fungals, anti-malarials, anti-tublerculosis agents, anti-virals, alpha
androgenergic
agonists, beta adrenergic blocking agents, carbonic anhydrase inhibitors, mast
cell
stabilizers, miotics, prostaglandins, antihistamines, anti-microtubule agents,
anti-
neoplastic agents, anti-poptotics, aldose reductase inhibitors, anti-
hypertensives,
antioxidants, growth hormone antagonists, vitrectomy agents adenosine receptor
antagonists, adenosine deaminase inhibitors, glycosylation antagonists, anti-
aging
peptides, topoisemerase inhibitors, anti-metabolites, alkylating agents, anti-
andrigens,
anti-oestogens, oncogene activation inhibitors, telomerase inhibitors,
antibodies or
portions thereof, antisense oligonucleotides, fusion proteins, luteinizing
hormone
releasing hormones agonists, gonadotropin releasing hormone agonists, tyrosine
kinase
inhibitors, epidermal growth factor inhibitors, ribonucleotide reductase
inhibitors,
cytotoxins, IL2 therapeutics, neurotensin antagonists, peripheral sigma
ligands,
endothelin ETA/receptor antagonists, anti-hyperglycemics, anti-glaucoma
agents, anti-
chromatin modifying enzymes, obesity management agents, anemia therapeutics,
emesis
therapeutics, neutropaenia therapeutics, tumor-induced hypercalcaemia
therapeutics,
blood anticoagulants, immunosuppressive agents, tissue repair agents,
insulins, glucagon-
like- peptides, botulinum toxins, and psychotherapeutic agents; and wherein
said
formulation provides for the sustained release of about 2% to about 100% of
the active
agent over a period ranging from about 1 day to about 365 days.
2a
CA 02582096 2012-12-06
Further, there is provided a pharmaceutical formulation for intraocular
injection for the
sustained release of an active agent comprising: at least one excipient
selected from the group
consisting of benzyl benzoate, ethyl benzoate, n-propyl benzoate, isopropyl
benzoate, n-butyl
benzoate and isobutyl benzoate; wherein the amount of the excipient is
sufficient to dissolve,
disperse, emulsify, or suspend the entire amount of the active agent in the
composition, and
wherein the concentration of excipient in the composition is higher than the
concentration of any
other constituent in the composition; wherein the composition releases the
active agent for a
period of at least about 60 days; and wherein the composition is a unit dosage
formulation of
about 5 ul to about 100 ul that can be injected through a 20 gauge or smaller
size syringe needle
into the subconjunctiva, periocular space, retrobulbar in the orbit,
episclera, intracornea,
intrasclera, anterior chamber, anterior segment, posterior chamber, posterior
segment, vitreous
cavity, subretinal space, suprachorodial segment or intraretinal area of the
eye, such that upon
initial injection said pharmaceutical composition maintains its monolithic
integrity.
Additionally, there is provided a use of a pharmaceutical formulation for
treating
inflammation or angiogenesis of the eye; wherein the formulation is injectable
into the vitreous of
the eye and consists of at least one anti-angiogenesis agent or anti-
inflammatory agent; and at
least one biocompatible, biodegradable excipient selected from the group
consisting of benzyl
benzoate, and triethyl, tripropyl, tributyl esters of citric acid and mono,
di, and tri esters of
0-acetylcitric acid with C1 to C10 straight and branched chain aliphatic
alcohols; wherein the
amount of the excipient is sufficient to dissolve, disperse, emulsify, or
suspend the entire amount
of the active agent in the composition, and wherein the concentration of
excipient in the
composition is higher than the concentration of any other constituent in the
composition; and
wherein the formulation releases into the vitreous a therapeutic dose of the
anti-angiogenesis
agent or anti-inflammatory agent for at least about sixty days.
Yet another embodiment provides for a pharmaceutical formulation for
implantation into
a patient for the sustained release of an active agent comprising a
biocompatible,
2b
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
biodegradable excipient and an active agent or pharmaceutically acceptable
salt thereof,
wherein about 2% to about 60% of the active agent is released over a period
ranging from
about 1 day to about 105 days. Alternatively, about 2% to about 100% of the
active agent
may be released over a period of about 25 days. Or about 2% to about 85% of
the active
agent may be released over a period of about 30 days to about 60 days. In
another
embodiment, about 2% to about 60% of the active agent is released over a
period ranging
from about 80 days to about 100 days.
In another aspect of the invention, the formulation comprises an active agent
at a
concentration from about 5% to about 50% of the implant and includes a
biodegradable,
biocompatible excipient at a concentration of at least about 5% percent of the
implant.
In another embodiment, the biocompatible, biodegradable excipient may be
tocopherol isomers and/or their esters; tocotrienols and/or their esters;
benzyl alcohol; benzyl
benzoate; those dibenzoate esters of poly(oxyethylene) diols having low water
solubility;
dimethyl sulfone; poly(oxypropylene) diols having low water solubility; the
mono, di, and
triesters of 0-acetylcitric acid with Ci-Cio straight and branched chain
aliphatic alcohols; and
liquid and semisolid polycarbonate oligomers.
An aspect of the invention provides for a controlled and sustained drug
delivery
system for the posterior segment of the eye, comprised of a biodegradable and
biocompatible
liquid matrix for direct injection. In particular, this aspect of the
invention provides for a
composition comprising dexamethasone or triamcinolone acetonide and benzyl
benzoate. In
an aspect of this embodiment, dexamethasone or triamcinolone acetonide is
released into the
vitreous of the eye in an amount ranging from about 20 Rg/m1 to less than
about 1.0 Rg/m1
over a period of about sixty to about ninety days.
The active agent envisioned in an embodiment of the present invention is
selected
from the group consisting of analgesics, anesthetics, narcotics, angiostatic
steroids, anti-
inflammatory steroids, angiogenesis inhibitors, nonsteroidal anti-
inflammatories, anti-
infective agents, anti-fungals, anti-malarials, anti-tublerculosis agents,
anti-virals, alpha
androgenergic agonists, beta adrenergic blocking agents, carbonic anhydrase
inhibitors, mast
cell stabilizers, miotics, prostaglandins, antihistamines, antimicrotubule
agents, antineoplastic
agents, antipoptotics, aldose reductase inhibitors, antihypertensives,
antioxidants, growth
hormone agonists and antagonists, vitrectomy agents, adenosine receptor
antagonists,
adenosine deaminase inhibitor, glycosylation antagonists, anti aging peptides,
topoisemerase
inhibitors, anti-metabolites, alkylating agents, antiandrigens, anti-
oestogens, oncogene
3
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
activation inhibitors, telomerase inhibitors, antibodies or portions thereof,
antisense
oligonucleotides, fusion proteins, luteinizing hormone releasing hormones
agonists,
gonadotropin releasing hormone agonists, tyrosine kinase inhibitors, epidermal
growth factor
inhibitors, ribonucleotide reductase inhibitors, cytotcodns, IL2 therapeutics,
neurotensin
antagonists, peripheral sigma ligancls, endothelin ETA/receptor antagonists,
antihyperglycemics, anti-glaucoma agents, anti-chromatin modifying enzymes,
insulins,
glucagon-like-peptides, obesity management agents, anemia therapeutics, emesis
therapeutics, neutropaenia therapeutics, tumor-induced hypercalcaemia
therapeutics, blood
anticoagulants, immunosuppressive agents, tissue repair agents,
psychotherapeutic agents,
botulinum toxins (Botox, Allergan), and nucleic acids such as siRNA and RNAi.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 presents dissolution profiles of dexamethasone (Dex) from two
formulations
of Dex/poly(1,3-propanediol carbonate)I.
Figure 2 presents dissolution profiles of Dex from two formulations of
Dex/poly(1,3-
propanediol carbonate)IL
Figure 3 represents dissolution profiles of Dex from three formulations of
Dex/poly(di-1,2 propylene glycol carbonate).
Figure 4 depicts dissolution profiles of Dex from two formulations of
Dex/poly(tri-1,2
propylene glycol carbonate).
Figure 5 depicts dissolution profiles of Dex released from three formulations
of
Dex/benzyl benzoate.
Figure 6 depicts dissolution profiles of Dex released from three formulations
of
Dex/diethylene glycol dibenzoate_
Figure 7 depicts dissolution profiles of triamcinolone acetonide released from
three
formulations of triamcinolone acetonide/diethylene glycol dibenzoate.
Figure 8 depicts dissolution profiles of Dex released from three formulations
of Dex/d-tocopherol, and dl-tocopheryl acetate..
Figure 9 depicts a dissolution profile of Dex released from a Dex/diethylene
glycol
dibenzoate formulation.
Figure 10 depicts a dissolution profile of Dex released from a Dex/benzyl
benzoate
formulation.
4
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
Figure 11 depicts a dissolution profile of Dex released from a Dex/tocopheryl
succinate formulation.
Figure 12 depicts a dissolution profile of Dex and Ciprofloxacin from a 1:1
formulation of those components in benzyl benzoate (Panel A) and a 3:1
formulation of Dex
and Ciprofloxacin in benzyl benzoate (Panel B).
Figure 13 depicts the concentration of Dex released into the vitreous humor
from two
formulation of Dex in benzyl benzoate.
Figure 14 represents a histopathological slide of rabbit eye tissue thirty
days after a
posterior segment injection of a formulation of 25% Dex in benzyl benzoate.
Figure 15 depicts the vitreous concentration of tramcinolone acetonide (TA)
released
from a TA benzyl benzoate composition.
Figure 16 depicts the in vivo release of Dex released into the aqueous humor
from a
Dex/dl-alpha tocopherol succinate formulation.
Figure 17 depicts the dissolution of Dex from a Dex/acetone/tocopherol
succinate
formulation applied to solid surfaces.
Figure 18 shows the dissolution profile of cyclosporin from a cyclosporine/
tocopherol succinate formulation.
Figure 19 depicts an in vivo release profile of cyclosporine from a tocopherol
succinate:cyclosporin formulation implanted the anterior chamber of a NZW
rabbit.
Figure 20 depicts an in vivo release profile of cyclosporine from a tocopherol
succinate:cyclosporin formulation implanted the posterior segment of a NZW
rabbit eye.
Figure 21 shows an in vivo release of cyclosporine from a tocopherol
succinate:cyclosporin formulation implanted in the peritoneal cavity of a rat.
Figure 22 plots in vivo blood glucose levels in mice treated with a
transdermal
formulation of insulin in tocopheryl acetate.
DETAILED DESCRIPTION OF THE INVENTION
It should be understood that this invention is not limited to the particular
methodology, protocols, and reagents, etc., described herein and as such may
vary. The
terminology used herein is for the purpose of describing particular
embodiments only, and is
not intended to limit the scope of the present invention, which is defined
solely by the claims.
As used herein and in the claims, the singular forms "a," "an," and "the"
include the
plural reference unless the context clearly indicates otherwise. Thus, for
example, the
5
CA 02582096 2012-02-02
reference to an excipient is a reference to one or more such excipients,
including equivalents
thereof known to those skilled in the art. Other than in the operating
examples, or where
otherwise indicated, all numbers expressing quantities of ingredients or
reaction conditions used
herein should be understood as modified in all instances by the term "about."
The term "about" =
when used in connection with percentages may mean 1 (Yo.
All patents and other publications identified herein are intended for the
purpose of
describing and disclosing, for example, the methodologies described in such
publications that
might be used in connection with the present invention, but are not to provide
definitions of terms
inconsistent with those presented herein. These publications are provided
solely for their
disclosure prior to the filing date of the present application. Nothing in
this regard should be
construed as an admission that the inventors are not entitled to antedate such
disclosure by virtue
of prior invention or for any other reason.
Unless defined otherwise, all technical and scientific terms used herein have
the same
meaning as those commonly understood to one of ordinary skill in the art to
which this invention
pertains.
The present invention relates to novel biocompatible, biodegradable sustained
release
formulations. In one aspect of the invention, these formulations are
syringeable liquids,
mechanically cohesive solids, injectable gels, or emulsified micells (oil in
water or water in oil).
A desirable feature of these liquid, solid, and gel formulations is that they
maintain a single bolus
or pellet shape at the site of their placement. That is, they do not break up
as a multitude of
smaller droplets or particles that migrate away from their intended point of
placement and/or by
virtue of a resultant increase in surface area greatly alter the intended
release rate of their drug
content.
The formulations of the present invention provide for novel therapies that are
easily
manipulated and injected or implanted by qualified medical practitioners. The
formulations
deliver therapeutic and non-toxic levels of active agents over the desired
extended time
6
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
frame, primarily at the site of implantation. The formulations are both
biocompatible and
biodegradable, and disappear harmlessly after delivering active agent to the
desired site.
The present invention relates generally, but not totally, to the use of
formulations that
are of limited solubility, biocompatible, and biodegradable (LSBB), which may
also be
syringeable, for controlled and sustained release of an active agent or a
combination of active
agents. Solid, gel, or injectable controlled-sustained release systems can be
fabricated by
combining LSBB and an active agent. Systems can combine more than one
biodegradable
component as well as more than one active agent. Solid forms for implantation
can be
produced by tableting, injection molding or by extrusion. Gels can be produced
by vortex cir
mechanical mixing. Injectable formulations can be made by pre-mixing in a
syringe or
mixing of the LSBB and the active agent before or at the time of
administration.
Formulations may serve as coating for stents or other implants by, for
example, dipping th
stent in a liquid form of the formulation and then drying it.
In an aspect of the present invention, novel biocompatible and biodegradable
syringeable liquid, implantable cohesive solids, and injectable gel
formulations conveniently
placed on or within the human or animal body for the sustained release of
active agents, are
obtained by admixing one or more excipients, such as, for example: benzyl
alcohol; benzyl
benzoate; diethylene glycol dibenzoate; triethylene glycol dibenzoate;
dibenzoate esters of
poly(oxyethylene) diols up to about 400 mwt; propylene glycol dibenzoate;
dipropylene
glycol dibenzoate; tripropylene glycol dibenzoate; dibenzoate esters of
poly(oxypropylen)
diols up to about 3000 mwt; poly(oxypropylene) diols up to about 3000 mwt;
dimethyl
sulfone; the various isomers of tocopherol; tocopherol acetate and tocopherol
succinate,
tocotrienol isomers and their esters, perfluorohexane, polymeric polycarbonate
oligomers,
and the mono, di, and triesters of 0-acetylcitric acid with C1-C10 straight
and branched chain
aliphatic alcohols, with a large number of established and new active agents.
In another aspect of the invention, the solid form generally contains about 1%
to
about 60% of an LSBB, the gel form generally contains about 20% to about 80%
of an
LSBB, and an injectable form (which may be a gel or liquid form) generally
contains about
30% to about 99.9% of an LSBB.
Liquid and Solid LSBBs can be implanted, for example, surgically, by trocar,
or by
needle introduction. It can be placed into body cavities such as joints by
methods well-known
in the art (typically using the procedures outlined by Cardone & Tallia, Am.
Family
Physician, 66(2), 283-92 (2002); 66(11), 2097-100 (2002); 67(10), 2147-52
(2003); 68(7),
7
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
1356-62 (2003); 67(4), 745-50 (2003)); intraocular (chambers such as the
anterior chamber
and posterior segment of the eye); intratumoral injection into the prostate
tumor (typically
using a procedure similar to that described by Jackson et al., 60(5) Cancer
Res., 4146-51
(2000)); intratumoral injection into inoperable tumors (such as gliomas) in
the brain
(typically using a procedure similar to that described by Emerich et al.,
17(7) Pharm
Res, 767-75 (2000)); injection or insertion into an intravertebral disc or
disc space; injection
into peritoneal cavity or, intranasal, intrathecal, subcutaneous, or
intramuscular
injection,injection into the epidural, subdural and/or subarachnoid space; or
it can be injected
or inserted directly into the cerebral spinal fluid through the spinal canal
or into the CNS
ventricular system.
Additionally, for localized active agent delivery, the system of the present
invention
may be surgically implanted at or near the site of action. This may be useful
when it is used,
for example, in treating ocular conditions, primary tumors, rheumatic and
arthritic conditions,
and chronic pain.
It is contemplated that these LSBB/active agent compositions can be applied to
the
following, but not limited to, systems of the human or animal body: muscular,
skeletal,
nervous, autonomic nervous, vascular, lymphatic, digestive, respiratory,
urinary, female
reproductive, male reproductive, endocrine or intraparenchymal, to provide a
wide variety of
sustained therapies.
Specific areas of the human or animal body to be targeted for injection or
implantation or topical applications of these LSBB/active agents compositions
include, but
are not limited to: heart, brain, spinal nerves, vertebral column, skull,
neck, head, eye, ear
organs of hearing and balance, nose, throat, skin, viscara, hair, shoulder,
elbow, hand, wrist,
hip, knee, ankle, foot, teeth, gums, liver, kidney, pancreas, prostate,
testicles, ovaries, thymus,
adrenal glands, pharynx, larynx, bones, bone marrow, stomach, bowel, upper and
lower
intestines, bladder, lungs, mammaries. Surgical mplantation into the eye, for
example, is
known in the art as described in U.S. Patents No. 6,699,493; No. 6,726,918;
No. 6,331,313;
No. 5,824,072; No. 5,766,242; No. 5,443,505; No. 5,164,188; No. 4,997,652; and
No.
4,853,224.
Solid LSBB, for example, may be implanted directly into parenchymal tissues
such as
the brain, spinal cord, or any part of the CNS system, into the kidney, liver,
spleen, pancreas,
lymph nodes as well as tumors. Gel LSBB systems may be applied to surface
tissues such as
=the skin, or as coating on surfaces of parenchymal organs to be absorbed, or
be applied
8
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
directly on the cornea, conjunctiva and on the sclera for delivery of active
agent onto the
surface and intraocularly of the eye. Injectable LSBB is less invasive and can
be delivered,
for example, through a 30 gauge needle into the eye, or through larger needles
into cavities
like joints.
The system according to the present invention has particular applicability in
providing
a controlled and sustained release of active agents effective in obtaining a
desired local or
systemic physiological or pharmacological effect relating at least to the
following areas:
treatment of cancerous primary tumors, chronic pain, arthritis, rheumatic
conditions,
hormonal deficiencies such as diabetes and dwarfism, modification of the
immune response
such as in the prevention and treatment of transplant rejection and in cancer
therapy. The
system is also suitable for use in treating HIV and HIV related opportunistic
infections such
as CMV, toxoplasmosis, pneumocystis carinii and mycobacterium avium
intercellular. The
system may be used to delivery an active agent effective in treating fungal
infection of the
mouth. If such a use is desired, the system may be designed to have a shape
suitable for
implanting into a tooth.
LSBB is also useful for treating ocular conditions such as glaucoma, PVR,
diabetic
retinopathy, uveitis, retinal edema, vein occulusion, macular degeneration,
Irvine-Gass
Syndrome and CMV retinitis, corneal diseases such as keratitis and corneal
transplantation
and rejection. The formulations may also be prepared as control release eye
drops for dry-eye
or for controlling the immune response. Regarding control of immune responses,
the
formulations may contain cyclosporine, sirolimus, or tacrolimus. Other
intraocular uses
include glaucoma treatments (formulations including timolol), antibiotic
delivery,
antiproliferatives delivery (e.g., paclitaxel).
Other uses of the formulations include, for example, mediating homograft
rejection
with formulations comprising surolimus or cyclosporine. Local cancer therapy
may be
delivered to, for example, the kidney or liver, using in formulations
comprising, for example,
adriamycin or small epidermal growth factors. Prostate cancer may be treated
with
formulations including fenasteride. Cardiac stents implants, central nervous
system implants
(e.g., spinal implants), orthopedic implants, etc., may be coated with
formulations including
growth or differentiation factors, anti-inflammatory agents, or antibiotics.
The technology of the present application is useful in overcoming the
difficulties
reported in some cases of achieving therapeutic efficacy, as experienced in
current
administrations requiring large doses of medications that may result in toxic
side effects. An
9
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
important example of this problem is the current clinical practice of
intravitreal injections of
microcrystalline triamcinolone acetonide (TA) for the treatment of intraocular
neovascular,
oedematous, or inflammatory diseases. See Jonas et al., 24(5) Prog Retin Eye
Res. 587-611
(2005), and references therein. The therapy requires the presence of a
solution of the proper
TA concentration in the vitreous chamber for periods of six months to a year
and possibly
longer. The therapeutic vitreal concentrations of TA seem to be at 1.0 g/m1
or below
(Matsuda et al., 46 Invest Ophthalmol Vis Sci. 1062-1068 (2005)) whereas
harmful
complications (glaucoma, cataracts, cytotoxicity) can arise when TA
concentrations
continuously exceed 10 g/ml over an extended period of time. See Gillies et
al., 122(3) Arch
Ophthalmol. 336-340 (2004); Jonas et al., 15(4) Eur J Ophthalmol. 462-4
(2005); Yeung et
al, 44 Invest Ophthalmol Vis Sci. 5293-5300 (2003). The desire to limit TA
administration to
one or two injections per year (obvious patient comfort coupled with the
possibility of
endophthalmitis (see Bucher et al., 123(5) Arch Ophthalmol. 649-53 (2005)),
conflicts with
the ability of supplying enough TA crystals without excursions into toxic
concentrations. The
novel compositions of this invention solve this problem by encompassing the
desired
amounts of TA crystals in an injectable, biocompatible, bioerodable medium
that
continuously regulates the release of safe, therapeutic levels of intravitreal
TA for periods of
six months or more.
Further regarding ocular conditions, metabolic and inflammation conditions in
the
posterior segment of the eye have been extremely difficult to treat. Such
conditions as
proliferative vitreoretinopathy (PVR), uveitis, cystoid macular edema (CME),
diabetes, and
macular degeneration are major causes of blindness. Conventional methods of
drug delivery,
including topical, periocular, subconjunctival or systemic administration,
have had limited
success due in large part to poor drug penetration (due to the blood-eye
barrier) and toxic side
effects. One efficient way of delivering a drug to the posterior segment is to
place it directly
into the vitreous cavity. Intravitreal drug injections have shown promising
results in animals
and in humans, but repeated and frequent injections have had to be performed
to maintain
therapeutic levels.
For example, direct injection of corticosteroids, particularly triamcinolone
acetonide,
has been effective particularly in selected wet AMD and in diabetic retinal
edemas. Because
of the drug's short half-life in the eye, frequent injections are required.
Moreover, because the
drug is being given in a bolus, uncontrolled high and then low drug
concentration levels are
encountered. As a consequence, adverse reactions such as infection, glaucoma,
cataract
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
formation, retinal detachment and intraocular bleeding have been common
adverse
occurrences. Vitrasert (Bausch & Lomb) is a six to eight month reservoir
system to treat
CMV retinitis with the antiviral gancyclovir. This is a non-biodegradable
system and must be
both inserted and removed surgically. Similarly, Posurdex (Allergan Pharma)
is a one-
month biodegradable delivery system that must be implanted surgically into the
eye, and
contains dexamethasone and PLGA for the treatment of posterior segment
pathologies.
Hence, one embodiment of the present invention provides for an intraocular
controlled and sustained drug delivery system for the posterior segment of the
eye. It is
comprised of a biodegradable and biocompatible liquid matrix containing a
microdispersed
drug or mixture of drugs, and can be injected directly into the posterior
segment with a
relatively small needle. The duration of drug delivery can be as short as a
few days to many
months and up to one year or longer, and the matrix gradually and safely
dissipates over time
so that there is no need to remove it. An example embodiment comprises
dexamethasone and
benzyl benzoate. In this system, intravitreal levels of dexamethasone with a
25% formulation
in 50 gl delivers a mean vitreous level of approximately 8.0 g/m1 over a three-
month period.
In comparison, a 25 ttl injection delivers a mean vitreous level of
approximately 4.0 p.g/rnl
over a sixty day period. This composition is biocompatible, biodegradable, non-
toxic, easy to
manufacture, easy to deliver, and flexible in terms of therapeutic dose and
duration of
delivery.
A wide variety of other disease states are known by those of ordinary skill in
the art,
such as those described in Goodman & Gilman, THE PHARMACOLOGICAL BASIS OF
THERAPEUTICS (McGraw Hill, 2001), and REMINGTON'S PHARMACEUTICAL SCIENCES
(Lippincott Williams & Wilkins; 20th ed., 2000). Those to which the present
invention may
be applied may be determined by those with ordinary skill in the art without
undue experimentation.
Suitable classes of active agents for use in the system of the present
invention include,
but are not limited to the following:
Peptides and proteins such as cyclosporin, insulins, glucagon-like- peptides,
growth hormones, insulin related growth factor, botulinum toxins (Botox,
Allergan), and heat
*shock proteins;
Anesthetics and pain killing agents such as lidocthne and related compounds,
and benzodiazepam and related compounds;
11
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
Anti-cancer agents such as 5-fluorouracil, methotrexate and
related compounds;
Anti-inflammatory agents such as 6-mannose phosphate;
Anti-fungal agents such as fluconazole and related compounds;
Anti-viral agents such as trisodium phosphomonoformate, trifluorothymidine,
acyclovir, cidofovir, ganciclovir, DDI and AZT;
Cell transport/mobility impending agents such as colchicines, vincristine,
cytochalasin B and related compounds;
Anti-glaucoma drugs such as beta-blockers: timolol, betaxolol atenolol;
Immunological response modifiers such as muramyl dipeptide and
related compounds;
Steroidal compounds such as dexamethasone, prednisolone, and
related compounds; and
Carbonic anhydrase inhibitors.
In addition to the above agents, other active agents which are suitable for
administration, especially to the eye and its surrounding tissues, to produce
a local or a
systemic physiologic or pharmacologic effect can be used in the system of the
present
invention. Examples of such agents include antibiotics such as tetracycline,
chloramphenicol,
ciprofloxacin, ampicillin and the like.
Any pharmaceutically acceptable form of the active agents of the present
invention
may be employed in the practice of the present invention, e.g., the free base
or a
pharmaceutically acceptable salt or ester thereof. Pharmaceutically acceptable
salts, for
instance, include sulfate, lactate, acetate, stearate, hydrochloride,
tartrate, maleate, citrate,
phosphate and the like.
The active agents may also be used in combination with pharmaceutically
acceptable
carriers in additional ingredients such as antioxidants, stabilizing agents,
and diffusion
enhancers. For example, where water uptake by the active agent is undesired,
the active agent
can be formulated in a hydrophobic carrier, such as a wax or an oil, that
would allow
sufficient diffusion of the active agent from the system. Such carriers are
well known in the
art.
In another aspect of the invention, a low solubility active agent may be
combined with
a biodegradable, biocompatible excipient of higher solubility to result in an
LSBB
formulation. For example, dimethyl sulfone may be used as a binder in an LSBB
formulation
12
CA 02582096 2012-02-02
of a limited solubility active agent. Hence, the use of a soluble excipient in
an LSBB formulation
is within the scope of the present invention.
In one embodiment, the active agents, e.g., proteins, may be formulated in a
glassy matrix
of sugar which tends to protect the active agent from hydrolytic degradation
and extend their
shelf life and eliminate the need for cold storage. See, for example, Franks,
Long Term
Stabilization of Biologicals, 12 Bio/Technology 253-56 (1994).
Proteins may be formulated in a glass matrix by removing water from a
homogeneous
solution thereof. The water can be removed either by evaporation or by rapidly
cold quenching
the solution. The process is commonly referred to as vitrification. As water
is removed from the
solution, it becomes increasingly viscous until a "solidified" liquid
containing the proteins is
obtained. The "solidified" liquid is generically called glass.
Glasses have a number of unique physical and chemical properties which make
them
ideal for active agent formulation. Among them, the most important is that the
solidified liquid
retains the molecular disorder of the original solution. This disorder
contributes to the glasses
long-term stability by preventing crystallization and chemical reactions of
the proteins encased
therein.
Sugars can also play an important part in stabilizing protein formulations. In
solution,
they are known to shift the denaturation equilibrium of proteins toward the
native state. Most
sugars, particularly low molecular weight carbohydrates, are also known to
vitrify easily and to
provide a glassy matrix that retards inactivating reactions of the proteins.
For illustrative purposes, the glassy sugar matrix for use in the system
according to the
present invention can be made by compressing a lyophilized mix of a protein
with sugar and a
buffer, and optionally, binders.
Examples of proteins and proteinaceous compounds which may be formulated and
employed in the delivery system according to the present invention include
those proteins which
have biological activity or which may be used to treat a disease or other
pathological condition.
They include, but are not limited to growth hormone, Factor VIII, Factor IX
and other
coagulation factors, chymotrypsin, trysinogen, alpha-interferon, beta-
galactosidase, lactate
dehydrogenase, growth factors, clotting factors, enzymes, immune response
stimulators,
cytokines, lymphokines, interferons, immunoglobulins, retroviruses,
interleukins, peptides,
somatostatin, somatotropin analogues, somatomedin-C, Gonadotropic releasing
hormone,
follicle stimulating hormone, luteinizing hormone, LH'RH, LHRH analogues such
13
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
as leuprolide, nafarelin and geserelin, LHRH agonists and antagonists, growth
hormone
releasing factor, callcitonin, colchicines, gonadotropins such as chorionic
gonadotropirt,
oxytocin, octreotide, somatotropin plus and amino acid, vasopressin,
adrenocorticotrophic
hormone, epidermal growth factor, prolactin, somatotropin plus a protein,
cosyntropin,
lypressin, polypeptides such as thyrotropin releasing hormone, thyroid
stimulation hormone,
secretin, pancreozymin, enkephalin, glucagons, and endocrine agents secreted
internally and
distributed by way of the bloodstream.
Other agents, such as a1 antitrypsin, insulin, glucagon-like-peptides, and
other peptide
hormones, botulinum toxins (Botox, Allergan), adrenal cortical stimulating
hormone, thyroid
stimulating hormone, and other pituitary hormones, interferons such as a, p,
and 6 interferon,
erythropoietin, growth factors such as GCSFm GM-CSF, insulin-like growth
factor 1, tissue
plasminogen activator, CF4, dDAVP, tumor necrosis factor receptor, pancreatic
enzyes,
lactase, interleukin-1 receptor antagonist, interleukin-2, tumor suppresser
proteins, cytotoxic
proteins, viruses, viral proteins, recombinant antibodies, portions of
antibodies, and antibody
fragments and the like may be used. Analogs, derivatives, antagonists,
agonists, and
pharmaceutically acceptable salts of the above may also be used.
Other active agents encompassed in the present invention include prodrugs.
Because
prodrugs are known to enhance numerous desirable qualities of pharmaceuticals
(e.g.,
solubility, bioavailability, manufacturing, etc.) the pharmaceutical dosage
forms of the
present invention may contain compounds in prodrug form. Thus, the present
invention is
intended to cover prodrugs of the presently claimed active agents, methods of
delivering the
same, and compositions containing the same.
Analogues, such as a compound that comprises a chemically modified form of a
specific compound or class thereof, and that maintains the pharmaceutical
and/or
pharmacological activities characteristic of said compound or class, are also
encompassed in
the present invention. Similarly, derivatives such as a chemically modified
compound
wherein the modification is considered routine by the ordinary skilled
chemist, such as an
ester or an amide of an acid, protecting groups, such as a benzyl group for an
alcohol or thiol,
and tert-butoxycarbonyl group for an amine, are also encompassed by the
present invention.
The above agents are useful for the treatment or prevention of a variety of
conditions
including, but not limited to hemophilia and other blood disorders, growth
disorders,
diabetes, obesity, leukemia, hepatitis, renal failure, HIV infection,
hereditary diseases such as
cerebrosidase deficiency and adenoine deaminase deficiency, hypertension,
septic shock,
14
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
autoimmune disease such as multiple sclerosis, Graves disease, systemic lupus
erythematosus
and rheumatoid arthritis, shock and wasting disorders, cystic fibrosis,
lactose intolerance,
Crohn's disease, inflammatory bowel disease, gastrointestinal and other
cancers, and
management of bladder, prostatic, and pelvic floor disorders, and uterine
fibroid
(submucosal, subserosal, intramural, parasitic myomas, and seedling myomas)
management
(using for example but not limited to pirfenidone, human interferin-alpha,
GnRH antagonists,
Redoxifene, estrogen-receptor modulators). Additionally, the formulations of
the present
invention may be used to treat intracranial aneurysms by, for example,
introducing fibrogen
or plasmin.
It is further contemplated that topical formulations of these LSBBs with
active agents
can be applied for the transdermal administration of contraceptives, insulin
or GLP-1,
transdermal application for alopecia treatment or delivery of aspirin or other
small molecules,
smoking cessation agents, insulin, anti-obesity agents, antivirals (herpes
therapies), agents for
psoriasis therapies, agents for for alopecia therapies, agents for acne
therapies, agents for
erectile disfunction and antiparasitic agents, to name a few.
The protein compounds useful in the formulations of the present invention can
be
used in the form of a salt, preferably a pharmaceutically acceptable salt.
Useful salts are
known to those skilled in the art and include salts with inorganic acids,
organic acids,
inorganic bases, or organic bases.
Sugars useful for preparing the glassy matrix discussed previously include,
but are not
limited to, glucose, sucrose, trehalose, lactose, maltose, raffinose,
stachyose, maltodextrins,
cyclodextrins, sugar polymers such as dextrans and their derivatives, ficoll,
and starch.
Buffers useful for formulating the glassy matrix include, but not limited to
MES,
HEPES, citrate, lactate, acetate, and amino acid buffers known in the art.
The LSBB system comprising the glassy sugar matrix may be constructed of a
bioerodible polymer with low water permeability. Such polymers include
poly(glycolic acid),
poly(lactic acid), copolymers of lactic/glycolic acid, polyorthoesters,
polyanhydrides,
polyphosphazones, polycaprolactone. These polymers may be advantageous because
of their
slow erosion properties and low water uptake; thus, they should not undergo
undue changes
during the course of the active agent delivery.
Naturally occurring or synthetic materials that are biologically compatible
with body
fluids suitable for use in the present invention generally include polymers
such as
polyethylene, polypropylene, polyethylene terephthalate, crosslinked
polyester, polcarbonate,
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
polysulfone, poly(2-pentene), poly(methylmethacrylate), poly(1,4-phenylene),
polytetrafluoroethylene, and poly-ethylene-vinylacetate (EVA).
In an aspect of the present invention, the excipient is also biodegradable or
bioerodible. As used herein, the terms "bioerodible" and "biodegradable" are
equivalent and
are used interchangeably. Biodegradable excipients are those which degrade in
vivo, and
wherein erosion of the excipient over time is required to achieve the agent
release kinetics
according to the invention. Suitable biodegradable excipients may include but
are not limited
to, for example, poly(glycolic acid), poly(lactic acid), copolymers of
lactic/glycolic acid,
polyorthoesters, polyanhydrides, polyphosphazones, polycarbonates, and
polycaprolactone.
The use of polylactic polyglycolic acid is described in, for example, U.S.
Patent No.
6,699,493. See also U.S. Patent No. 5,869,079.
In another aspect of the invention, the excipient is biocompatible, meaning
that it does
not have undue toxicity or cause either physiologically or pharmacologically
harmful effects.
In another aspect of the invention, the excipient is biodegradable.
Examples of excipients that may be useful as biocompatible, biodegradable
and/or
bioerodible excipients in the present invention, as determined by one of
ordinary skill in the
art in light of this specification, without undue experimentation, include,
but are not
limited to:
d-a-tocopherol; d,l-a-tocopherol; d-P-tocopherol; d,l-P-tocopherol;
tocopherol; and d,l-ri-tocopherol (including acetate, hemisuccinate,
nicotinate, and succinate-
PEG ester forms of each of the foregoing); tocotrienol isomers, and their
esters;
benzyl alcohol;
benzyl benzoate;
diethylene glycol dibenzoate;
triethylene glycol dibenzoate;
dibenzoate esters of poly(oxyethylene) diols of up to about 400 mwt;
propylene glycol dibenzoate;
dipropylene glycol dibenzoate;
tripropylene glycol dibenzoate;
dibenzoate esters of poly(oxypropylen_e) diols of up to about 3000 mwt;
poly(oxypropylene) diols of up to about 3000 mwt;
dimethyl sulfone;
triethyl, tripropyl, and tributyl esters of 0-acetylcitrate;
16
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
triethyl, tripropyl, tributyl esters of citric acid; and
liquid to semisolid polycarbonate oligomers, such as, but not limited to,
those
prepared by the polymerization of trimethylene carbonate [poly(1,3-
propanediol carbonate)]
or the ester exchange polymerization of diethylene carbonate with aliphatic
diols or
polyoxyalkane diols [poly(di-1,2-propylene glycol carbonate) or poly(tri-1 ,2-
propylene
glycol carbonate)].
Another example of biodegradable/biocompatible excipients useful in the
present
invention are "tocols." Tocols refers to a family of tocopherols and
tocotrienals and
derivatives thereof, because tocopherols and tocotrienals are derivatives of
the simplest
tocopherol, 6-hydroxy-2-methyl-2-phytylchroman. Tocopherols are also lcnown as
a family
of natural or synthetic compounds commonly called Vitamin E. Alpha-tocopherol
is the most
abundant and active form of this class of compounds. Other members of this
class include p-,
7-, and 8-tocopherols and a-tocopherol derivatives such as tocopheryl acetate,
succinate,
nicotinate, and linoleate. Useful tocotrienols include d-8-tocotreinols, and d-
f3-, d-7-
tocotrienols, and their esters.
In addition to the excipients listed above, the following excipients having
very low
viscosities are valued not only by themselves as carriers of drugs for
injectable sustained
release (ISR) formulations, but also as additives to the ISR formulations of
the excipients
listed above to reduce their viscosities and therebye improve syringeability.
These include:
perfluorodecalin; perfluorooctane; perfluorohexyloctane; the cyclomethic ones,
especially
octamethylcyclotetrasiloxane; decamethylcyclopentasiloxane, and
dodecamethylcyclohexasiloxane polydimethylsiloxanes of viscosities below about
1000 cSt;
diethyl carbonate; and dipropylcarbonate.
It is also contemplated that these liquid and solid LSBBs/active agent
formulations
can be coatings on implanted surfaces, such as but not limited to, those on
catheters, stents
(cardiac, CNS, urinary,etc.), prothesis (artificial joints, cosmetic
reconstructions, and the
like), tissue growth scaffolding fabrics, or bones and teeth to provide a wide
variety of
therapeutic properties (such as but not limited to, anti-infection, anti-
coagulation, anti-
inflammation, improved adhasion, improved tissue growth, improved
biocompatibilty). These
surfaces can be from a wide variety of materials, such as but not limited to,
natural rubbers,
wood, ceramics, glasses, metals, polyethylene, polypropylene, polyurethanes,
polycarbonates,
polyesters, poly(vinyl actetates), poly(vinyl alcohols), poly(oxyethylenes),
17
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
poly(oxypropylenes), cellulosics, polypeptides, polyacrylates,
polymethacrylates,
polycarbonates and the like.
Active agents, or active ingredients, that may be useful in the present
invention, as
determined by one of ordinary skill in the art in light of this specification
without undue
experimentation, include but are not limited to:
Analgesics, Anesthetics, Narcotics such as acetaminophen; clonidine (Duraclon
Roxane) and its hydrochloride, sulfate and phosphate salts; oxycodene
(Percolone, Endo) and
its hydrochloride, sulfate, phosphate salts; benzodiazepine; benzodiazepine
antagonist,
flumazenil (Romazicon, Roche); lidocaine; tramadol; carbamazepine
(Tegretol,
Novartis); meperidine (Demerol, Sanofi-Synthelabo) and its hydrochloride,
sulfate,
phosphate salts; zaleplon (Sonata, Wyeth-Ayerst); trimipramine maleate
(Surmontil, Wyeth¨
Ayerst); buprenorphine (Buprenex, Reckitt Benckiser); nalbuphine (Nubain,
Endo) and its
hydrochloride, sulfate, phosphate salts; pentazocain and hydrochloride,
sulfate, phosphate
salts thereof; fentanyl and its citrate, hydrochloride, ssulfate, phosphate
salts; propoxyphene
and its hydrochloride and napsylate salts (Darvocet, Eli Lilly& Co.);
hydromorphone
(Dilaudid, Abbott) and its hydrochloride, sulfate, and phosphate salts;
methadone (Dolophinie,
Roxane) and its hydrochloride, sulfate, phosphate salts; morphine and its
hydrochloride,
sulfate, phosphate salts; levorphanol (Levo-dromoran, ICN) and its tartrate,
hydrochloride,
sulfate, and phosphate salts; hydrocodone and its bitartrate, hydrochloride,
sulfate, phosphate
salts;
Angiostatic and/or Anti-inflammatory Steroids such as anecortive acetate
(Alcon);
tetrahydrocortisol, 4,9(11)-pregnadien-17a,21-dio1-3,20-dione (Anecortave) and
its -21-
acetate salt; 11-epicortisol; 17a-hydroxyprogesterone; tetrahydrocortexolone;
cortisona;
cortisone acetate; hydrocortisone; hydrocortisone acetate; fludrocortisone;
fludrocortisone
acetate; fludrocortisone phosphate; prednisone; prednisolone; prednisolone
sodium
phosphate; methylprednisolone; methylprednisolone acetate; methylprednisolone,
sodium
succinate; triamcinolone; triamcinolone-16,21-diacetate; triamcinolone
acetonide and its -21-
acetate, -21-disodium phosphate, and -21-hemisuccinate forms; triamcinolone
benetonide;
triamcinolone hexacetonide; fluocinolone and fluocinolone acetate;
dexamethasone and its
21-acetate, -21-(3,3-dimethylbutyrate), -21-phosphate disodium salt, -21-
diethylaminoacetate, -21-isonicotinate, -21-dipropionate, and -21-palmitate
forms;
betamethasone and its -21-acetate, -21-adamantoate, -17-benzoate, -17,21-
dipropionate, -17-
va1erate, and -21-phosphate disodium salts; beclomethasone; beclomethasone
dipropionate;
18
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
diflorasone; diflorasone diacetate; mometasone furoate; and acetazolamide
(Diamox,
multimanufacturers);
Nonsteroidal Anti-inflammatories such as naproxin; diclofenac; celecoxib;
sulindac;
diflunisal; piroxicam; indomethacin; etodolac; meloxicam; ibuprofen;
ketoprofen; r-
flurbiprofen (Myriad); mefenamic; nabumetone; tolmetin, and sodium salts of
each of the
foregoing; ketorolac bromethamine; ketorolac bromethamine tromethamine (Acular
,
Allergan, Inc.); choline magnesium trisalicylate; rofecoxib; valdecoxib;
lumiracoxib;
etoricoxib; aspirin; salicylic acid and its sodium salt; salicylate esters of
alpha, beta, gamma-
tocopherols and tocotrienols (and all their d, 1, and racemic isomers);
methyl, ethyl, propyl,
isopropyl, n-butyl, sec-butyl, t-butyl, esters of acetylsalicylic acid;
Angiogenesis Inhibitors such as squalamine, squalamine lactate (MSI-1256F,
Genaear) and curcumin; Vascular Endothelial Growth Factor (VEGF) Inhibitors
including
pegaptanib (Macugen, Eyetech/Pfizer); bevacizumab (Avastin,
Genentech/generic);
Neovastat (Aeterna); PTK 787 (Schering/Novartis); Angiozyme (RibozymeChiron);
AZD
6474 (AstraZeneca); IMC-1C11 (Imclone); NM-3 (ILEX Oncology); S6668
(Sugen/Pharmacia); CEP-7055 (Cephalon); and CEP-5214 (Cephalon); Integrin
Antagonists
such as Vitaxin (Applied Molecular Evolution/Medimmune); S 137 (Pharmacia);
S247
(Pharmacia); ST 1646 (Sigma Tau); DPC A803350 (Bristol-Myers Squibb);and o-
guanudines
(3D Pharmaceuticals/generic); matrix metalloproteinase inhibitors such as
prinomastat (AG
3340, Pfizer/generic), (ISV-616, InSite Vision), (TIMP-3, NIH); S3304
(Shionogi); BMS
275291 (Celltech/Bristol-Myers Squibb); SC 77964 (Pharmacia); ranibizumab
(Lucentis,
Genentech); ABT 518 (Abbott); CV 247 (Ivy Medical); shark cartilage extract
(Neovastat,
Aeterna); NX-278-L anti-VEGF aptamer (EyeTech); 2'-0-mrthoxyethyl antisense C-
raf
oncogene inhibitor (ISIS-13650); vitronectin and osteopontin antagonists (3-D
Pharm);
combretstatin A-4 phosphate (CA4P, Oxigene); fab fragment a-V/P-1 integrin
antagonist
(Eos-200-F, Protein Design Labs); cc-v/13-3 integrin antagonist (Abbott);
urokinase
plasminogen activator fragment (A6, Angstrom Pharm.); VEGF antagonist (AAV-
PEDF,
Chiron); kdr tyrosine kinase inhibitor (EG-3306, Ark Therapeutics);
cytochalasin E (NIH);
kallikrinin-binding protein (Med. Univ. So. Carolina); combretastatin analog
(MV-5-40,
Tulane); pigment-epithelium derived growth factor (Med. Univ. SC); pigment-
epithelium
derived growth factor (AdPEDF, GenVec/Diacrin); plasminogen kringle (Med.
Univ. SC);
rapamycin; cytokine synthesis inhibitor/p38 mitogen-activated protein kinase
inhibitor (SB-
220025, GlaxoSmithKline); vascular endothelial growth factor antagonist (SP-
(V5.2)C,
19
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
Supratek); vascular endothelial growth factor antagonist (SU10944,
Sugen/Pfizer); vascular
endothelial growth factor antagonist (VEGF-R, Johnson & Johnson/Celltech);
vascular
endothelial growth factor antagonist (VEGF-TRAP, Regeneron); FGF1 receptor
antagonist/
tyrosine kinase inhibitor (Pfizer/Sugen); endostatin, vascular endothelial
growth factor
antagonist (EntreMed); bradylcinin B1 receptor antagonist (B-9858, Cortech);
bactericidal/permeability-increasing protein (BPI, Xoma); protein kinase C
inhibitor
(Hypericin, Kansai Med. U.); ruboxistaurinn mesylate (LY-333531, Eli Lilly &
Co.);
polysulphonic acid derivatives (Fuji Photo Film); growth factor antagonists
(TBC-2653,
TBC-3685, Texas Biotechnology); Tunica internal endothelial cell kinase
(Amgen);
Anti-infective Agents such as Anti-bacterials including aztreonam; cefotetan
and its
disodium salt; loracarbef; cefoxitin and its sodium salt; cefazolin and its
sodium salt;
cefaclor; ceftibuten and its sodium salt; ceftizoxime; ceftizoxime sodium
salt; cefoperazone
and its sodium salt; cefuroxime and its sodium salt; cefuroxime axetil;
cefprozil; ceftazidime;
cefotaxime and its sodium salt; cefadroxil; ceftazidime and its sodium salt;
cephalexin;
cefamandole nafate; cefepime and its hydrochloride, sulfate, and phosphate
salt; cefdinir and
its sodium salt; ceftriaxone and its sodium salt; cefixime and its sodium
salt; cefpodoxime
proxetil; meropenem and its sodium salt; imipenem and its sodium salt;
cilastatin and its
sodium salt; azithromycin; clarithromycin; dirithromycin; erythromycin and
hydrochloride,
sulfate, or phosphate salts ethylsuccinate, and stearate forms thereof;
clindamycin;
clindamycin hydrochloride, sulfate, or phosphate salt; lincomycin and
hydrochloride, sulfate,
or phosphate salt thereof; tobramycin and its hydrochloride, sulfate, or
phosphate salt;
streptomycin and its hydrochloride, sulfate, or phosphate salt; vancomycin and
its
hydrochloride, sulfate, or phosphate salt; neomycin and its hydrochloride,
sulfate, or
phosphate salt; acetyl sulfisoxazole; colistimethate and its sodium salt;
quinupristin;
dalfopristin; amoxicillin; ampicillin and its sodium salt; clavulanic acid and
its sodium or
potassium salt; penicillin G; penicillin G benzathine, or procaine salt;
penicillin G sodium or
potassium salt; carbenicillin and its disodium or indanyl disodium salt;
piperacillin and its
sodium salt; ticarcillin and its disodium salt; sulbactam and its sodium salt;
moxifloxacin;
ciprofloxacin; ofloxacin; levofloxacins; norfloxacin; gatifloxacin;
trovafloxacin mesylate;
alatrofloxacin mesylate; trimethoprim; sulfamethoxazole; demeclocycline and
its
hydrochloride, sulfate, or phosphate salt; doxycycline and its hydrochloride,
sulfate, or
phosphate salt; minocycline and its hydrochloride, sulfate, or phosphate salt;
tetracycline and
its hydrochloride, sulfate, or phosphate salt; oxytetracycline and its
hydrochloride, sulfate, or
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
phosphate salt; chlortetracycline and its hydrochloride, sulfate, or phosphate
salt;
metronidazole; rifampin; dapsone; atovaquone; rifabutin; linezolide; polymyxin
B and its
hydrochloride, sulfate, or phosphate salt; sulfacetamide and its sodium salt;
minocycline; and
clarithromycin;
Antifunga1s such as amphotericin B; pyrimethamine; flucytosine; caspofungin
acetate;
fluconazole; griseofulvin; terbinafin and its hydrochloride, sulfate, or
phosphate salt;
ketoconazole; micronazole; clotrimazole; econazole; ciclopirox; naftifine; and
itraconazole;
Antimalarials such as chloroquine and its hydrochloride, sulfate or phosphate
salt;
hydroxychloroquine and its hydrochloride, sulfate or phosphate salt;
mefloquine and its
hydrochloride, sulfate, or phosphate salt; atovaquone; proguanil and its
hydrochloride,
sulfate, or phosphate salt forms;
Antituberculosis Agents such as ethambutol and its hydrochloride, sulfate, or
phosphate salt forms; aminosalicylic acid; isoniazid; pyrazinamide';
ethionamide;
Antivirals such as amprenavir; interferon alfa-n3; interferon alfa-2b;
interferon
alfacon-1; peginterferon alfa-2b; interferon alfa-2a; lamivudine; zidovudine;
amadine
(Symmetrel, Endo) and its hydrochloride, sulfate, and phosphate salts;
indinavir and its
hydrochloride, sulfate, or phosphate salt; ganciclovir; ganciclovir sodium
salt; famciclovir;
rimantadine and its hydrochloride, sulfate, or phosphate salt; saquinavir
mesylate; foscarnet;
zalcitabine; ritonavir; ribavirin; zanamivir; delavirdine mesylate; efavirenz;
amantadine and
its hydrochloride, sulfate, or phosphate salt; palivizumab; oseltamivir and
its hydrochloride,
sulfate, or phosphate salt; abacavir and its hydrochloride, sulfate, or
phosphate salt;
valganciclovir and its hydrochloride, sulfate, or phosphate salt; valacyclovir
and its
hydrochloride, sulfate, or phosphate salt; didanosine; nelfinavir mesylate;
nevirapine;
cidofovir; acyclovir; trifluridine; penciclovir; zinc oxide; zinc salicylate;
zinc salts of all
isomers of tocopherol hemisuccnic acid; zinc salts of straight, branched,
saturated, and
unsaturated chain C2 to C20 aliphatic carboxylic acids; zinc pyruvate; zinc
lactate; zinc ester
complexes; and zinc acetoacetonate or zinc acetoacetic ester complexes;
Anti HIV/AIDS agents including stavudine, reverset (Pharmasset), ACH-126443
(Achillion), MIV-310 (Boehringer Ingelheim), Zerit1R(d4tT) (Bristol-Meyers
Squibb),
Ziagen (GlaxoSmithKline), Viroad (Glead), hivid (Roche), Emtriva (Gilead),
delavirdine
(Pfizer), AG-1549 (Pfizer), DPC-083 (Bristol-Myers Squibb), NSC-675451
(Advanced Life
Sciences), IMC-125 (Tibitec), azidicarbonamide, GPG-NH2 (Tripep), immunitin
(Colthurst),
cytolin (Cytodyn), HRG-214 (Virionyx), MDX-010 (Gilead), TXU-PAP (Wayne Hughes
21
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
Inst), proleukin (Chiron), BAY 50-4798 (Bayer), BG-777 (Virocell), Crixivan
(Merck),
Fuzeon (Hoff-La Roche), WF-10 (Oxo Chemie), Ad5 Gag vaccine (Merck), APL400-
003
and 047 (Wyeth), Remunex (Immune Response Corp.), MVA-BN Nef (Bavarian
Nordic),
GTU MultyHIV vaccine (FIT Biotech);
Insulins such as Novolog (aspart), Novolin R, Novolin N, Novolin L, Novolin
70/30,
and Novolog 70/30 (Novo Nordisk); Humalog (lispro) Humulin R, Humulin N,
Humulin L,
Humulin 50/50 and 70/30, and Humalog Mix 75/25 and 70/30 (Eli Lilly);
Ultralente (Eli
Lilly); Lantus (glargine, Aventis); porcine; and bovine insulins;
Glucagon-like Peptide-1 (G1p1) and analogs (for diabetes therapy and appetite
suppression, cardiac protection) (see Keiffer et al., 20 Endocr Rev., 876-913
(1999); Glpl
Receptor stimulators such as exendin-4, Exenatide and Exenatide LAR (Amylin
Pharma);
Liraglutide (Novo Nordisk); ZP-10 (Zealnad Pharma); Gip-I-albumin (Conjuchem);
and
Dpp-IV inhibitors (which inhibit enzyme attack on Glp-1) such as LAF237
(Novartis); MK-
0431 (Merck); BMS-477188 (Bristol-Myers Squibb); and GSK23A (GlaxoSmithKline);
Alpha Androgenergic Agonist such as brimonidine tartrate; Beta Adrenergic
Blocking
Agents such as betaxolol and its hydrochloride, sulfate, or phosphate salt;
levobetaxolol and
its hydrochloride, sulfate, or phosphate salt; and timolol maleate;
Carbonic Anhydrase Inhibitors such as brinzolamide; dorzolamide and its
drochloride,
sulfate, or phosphate salt; and dichlorphenamid;
Mast Cell Stabilizers such as pemirolast and its potassium salt; nedocromil
and its
sodium salt; cromolyn and its sodium salt;
Miotics (Cholinesterase Inhibitors) such as demecarium bromide;
Prostaglandins such as bimatoprost; travoprost; and latanoprost;
Antihistamines such as olopatadine and its hydrochloride, sulfate, or
phosphate salt
forms; fexofenadine and its hydrochloride, sulfate, or phosphate salt;
azelastine and its
hydrochloride, sulfate, or phosphate forms; diphenhydramine and its
hydrochloride, sulfate,
or phosphate forms; and promethazine and its hydrochloride, sulfate, or
phosphate forms;
Antimicrotubule Agents such as Taxoids including paclitaxel (Taxol,Bristol-
Myers
Squibb); vincristine (Oncovin, Eli Lilly & Co.) and its hydrochloride,
sulfate, or phosphate
salt forms; vinblastine (Velbe, Eli Lilly & Co.) and its hydrochloride,
sulfate, or phosphate
salt; vinorelbine (Novelbinr, Fabre/GSK); cokhicines; docetaxel (Taxotere,
Aventis); 109881
(Aventis); LIT 976 (Aventis); BMS 188797 (Bristol-Myers Squibb); BMS 184476
(Bristol-
Myers Squibb); DJ 927 (Daiichi); DHA paclitaxel (Taxoprexin, Protarga);
Epothilones
22
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
including epothiloneB (EPO 906, Novartis/generic); BMS 247550 (Bristol-Myers
Squibb);
BMS 310705 (Bristol-Myers Squibb); epothilone D (KOS 862, Kosan/generic); and
ZK EPO
(Schering AG);
Antineoplastic agents such as doxorubicin and its hydrochloride, sulfate, or
phosphate
salt; idarubicin and its hydrochloride, sulfate, or phosphate salt;
daunorubicin and its
hydrochloride, sulfate, or phosphate salt; dactinomycin; epirubicin and its
hydrochloride,
sulfate, or phosphate salt; dacarbazine; plicamycin; mitoxantrone (Novantrone,
OSI
Pharmaceuticals) and its hydrochloride, sulfate, or phosphate salt;
valrubicin; cytarabine;
nilutamide; bicalutamide; flutamide; anastrozole; exemestane; toremifene;
femara; tamoxifen
and tamoxifen citrate; temozolimide (Temador); gemcitabine and its
hydrochloride, sulfate,
or phosphate salt; topotecan and its hydrochloride, sulfate, or phosphate
salt; vincristine and
its hydrochloride, sulfate, or phosphate salt; liposomal vincristine (Onco-
TCS, InexiElan);
methotrexate and methotrexate sodium salt; cyclophosphamide; estramustine
sodium
phosphate; leuprolide and leuprolide acetate; goserelin and goserelin acetate;
estradiol ;
ethinyl estradiol; Menest esterified estrogens; Premarin conjugated estrogens;
5-flurouracil;
bortezamib (Velcade, Millenium Pharmaceuticals);
Antiapoptotics such as desmethyldeprenyl (DES, RetinaPharma);
Aldose Reductase Inhibitors such as GP-1447 (Grelan); NZ-314 (parabanic acid
derivative, Nippon Zoki); SG-210 (Mitsubishi Pharma/Senju); and SJA-7059
(Senju);
Antihypertensives such as candesartan cilexetil (Atacand/Biopress,
Takeda/AstraZeneca/Abbott); losartan (Cozaar, Merck); and lisinopril
(Zestril/Prinivil,
Merck/AstraZeneca);
Antioxidants such as benfotiamine (Albert Einstein Col. Of Med./WorWag
Pharma);
ascorbic acid and its esters; tocopherol isomers and their esters; and
raxofelast (IRFI-005,
Biomedica Foscama);
Growth Hormone Antagonists such as octreotide (Sandostatin, Novartis); and
pegvisomant (Somavert, Pfizer/Genentech);
Vitrectomy Agents such as hyaluronidase (Vitrase, ISTA Pharm./Allergan);
Adenosine Receptor Antagonist such as A2B adenosine receptor antagonist (754,
Adenosine Therapeutics);
Adenosine Deaminase Inhibitor such s pentostatin (Nipent, Supergen);
Glycosylation Antagonists such as pyridoxamine (Pyridorin, Biostratum);
23
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
Anti-Ageing Peptides, such as Ala-Glu-Asp-Gly (Epitalon, St Petersburg Inst.
Bioreg.
and Geron);
Topoisomerase Inhibitors such as doxorubicin (Adriamycin/Caelyx,
Pharmacia/generics); daunorubicin (DaunoXome, Gilead/generics); etoposide
(Vepecid/Etopophos, Bristol-Myers Squibb/generics; idarubicin (Idamycin,
Pharmacia);
irinotecan (Camptosar, Pharmacia); topotecan (Hycamtin, GlaxoSmithKline);
epirubicin
(Ellence, Phamacia); and raltitrexed (Tomudex, AstraZeneca);
Anti-metabolites such as methotrexate (generic) and its sodium salt; 5-
fluorouracil
(Adrucil, ICN Pharmacia); cytarabine (Cytosar, Pharmacia/generic); fludarabine
(Fludara,
Scherimg) and its forms as salts with acids; gemcitabine (Gemsar, Eli Lilly&
Co.);
capecitabine (Xeloda, Roche); and perillyl alcohol (POH, Endorex);
Alkylating Agents such as chlorambucil (Leukeran, GlaxoSmithKline);
cyclophosphamide (Cytoxan, Pharmacia/Bristol- Meyers Squibb);
methchlorethanine
(generic); cisplatin (Platinal, Pharmacia/Bristol-Meyers Squibb); carboplatin
(Paraplatin,
Bristol-Myers Squibb); temozolominde (Temodar) and oxalipla-tin (Sanofi-
Synthelabs);
Anti-androgens such as flutamide (Eulexin, AstraZeneca); nilutamide (Anandron,
Aventis); bicalutamide (Casodex, AstraZeneca);
Anti-oestrogens such as tamoxifen (Nolvadex, AstraZeneca); toremofine
(Fareston,
Orion/Shire); Faslodex (AstraZeneca); arzoxifene (Eli Lilly & Co.); Arimidex
(AstraZeneca);
letrozole (Femera, Novartis); Lentaron (Novartis); Aromasin (Pharmacia);
Zoladex
(AstraZeneca); lasoxifene (CP ¨366,156, Pfizer); ERA-923 (Ligand/Wyeth); DCP
974
(DuPont/Bristol Myers Squibb); ZK 235253 (Shering AG); ZK1911703 (Shering AG);
and
ZK 230211 (Shering AG);
Oncogene Activation Inhibitors, including for example, Bcr-Abl Kinase
Inhibition
such as Gleevec (Novartis); Her2 Inhibition such as trastuzumab (Herceptin,
Genentech);
MDX 210 (Medarex); ElA (Targeted Genetics); ME103 (Pharmexa); 2C4 (Genentech);
Cl-
1033 (Pfizer); PK1 166 (Novartis); GW572016 (GlaxoSmithKline) and ME104
(Pharmexa);
EGFr Inhibitors such as Erbitux (Imclone/Bristol-Myers Squibb/Merck KgaA);
EGFr
Tyrosine Kinase Inhibitors such as gefitinib (Iressa ZD 1839, AstraZeneca);
cetwdmab
(Erbitux, Imclone/BMS/Merck KGaA); erlotinib (Tarceva, OSI
Pharmaceutical/Genentech/Roche); ABX-EGF (Abgenix); C1-1033 (Pfizer); EMD
72000
(Merck KgaA); GW572016 (GlaxoSmithKline); EKB 569 (Wyeth); PM 166 (Novartis);
and
BIBX 1382 (Boehringer Ingleheim); Famesyl Transferase Inhibitors such as
tipifamib
24
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
(Zarnestra, Johnson & Johnson); ionafarnib (Sarasar, Schering-Plough); BMS-
214,662
(Bristol-Myers Squibb); AZ3409 (AstraZeneca); CP-609,754 (OSI
Pharmaceuticals); CP-
663,427 (OSI Pharmaceuticals/Pfizer); Arglabin (NuOncology); RPR-130401
(Aventis); A
176120 (Abbott); BIM 46228 (Biomeasure); LB 42708 (LG Chem); LB 42909 (LG
Chem);
PD 169451 (Pfizer); and SCH226374 (Schering-Plough); Bc1-2 Inhibitors such as
BCL-X
(Isis); ODN 2009 (Novartis); GX 011 (Gemin X); and TAS 301 (Taiho); Cyclin
Dependent
Kinase Inhibitors such as flavopiridol (generic, Aventis); CYC202 (Cyciacel);
BMS 387032
(Bristol-Myers Squibb); BMS 239091 (Bristol-Myers Squibb); BMS 250904 (Bristol-
Myers
Squibb); CGP 79807 (Novartis); NP102 (Nicholas Piramal); and NU 6102
(AstraZeneca);
Protein Kinase C Inhibitors such as Affinitac (Isis, Eli Lilly & Co.);
midostaurin (PKC 412,
Novartis/generic); bryostatin (NCl/GPC Biotech/generic); KW 2401 (NCl/Kyowa
Hakko);
LY 317615 (Eli Lilly & Co.); perifosine (ASTA Medica/Baxter/generic); and
SPC 100840 (Sphinx);
Telomerase Inhibitors such as GRN163 (Geron/Kyowa Hakko) and
G4T 405 (Aventis);
Antibody Therapy including Herceptin (Genentech/Roche); MDX-H210 (Medarex);
SGN-15 (Seattle Genetics); H11 (Viventia); Therex (Antisoma); rituximan
(Rituxan,
Genentech); Campath (ILEX Oncology/Millennium/Shering); Mylotarg
(Celltech/Wyeth);
Zevalin (IDEC Pharmaceuticals/Schering); tositumomab (Bexxar,
Corixa/SmithKline
Beecham/Coulter); epratuzumab (Lymphocide, 1mmunomedics/Amgen); Oncolym
(Techniclone/Schering AG); Mab Hu1D10 antibody (Protein Design Laboratories);
ABX-
EGF (Abgenix); infleximab (Remicadee, Centocor) and etanercept (Enbrel, Wyeth-
Ayerst);
Antisense Oligonucleotides such as Affinitac (Isis Pharmaceuticals/Eli Lilly &
Co.);
and Genasence (GentaJAventis);
Fusion Proteins such as denileukin diftitox (Ontak, Ligand);
Luteineizing Hormone Releasing Hormone (LHRH) Agonists aka Gonadotropin
Releasing Hormone (OnRH) Agonists such as goserelin (Zoladex, AstraZeneca);
leuporelin
(Lupron, Abbott/Takeda); leuporelin acetate implant (Viadur, ALZA/Bayer and
Atigrel/Eligard, Atrix/Sanofi-Synthelabo); and triptorelin (Trelstar,
Pharmaceuticals);
Tyrosine Kinase Inhibitors/Epidermal Growth Factor Receptor Inhibitors such as
gefitinib (Iressa, AstraZeneca, ZT) 1839); trastuzumab (Herceptin, Genentech);
erlotinib
(Tarceva, OSI Pharnnaceuticals, OSI 774); cetuximab (Erbitux, Imclone Systems,
ILVIC 225);
and pertuzumab (Omnitarg, Genentech, 2C4);
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
Ribonucleotide Reductase Inhibitors such as gallium maltolate (Titan);
Cytotoxins such as Irofulven (VIGI 114, MGI Pharma);
IL2 Therapeutics such as Leuvectin (Vical);
Neurotensin Antagonist such as SR 48692 (Sanofi-Synthelabo);
Peripheral Sigma Ligands such as SR 31747 (Sanofi-Synthelabo);
Endothelin ETA/Receptor Antagonists such as YM-598 (Yamanouchi); and
atrasentan (ABT-627, Abbott);
Antihyperglycemics such as metformin (Glucophage, Bristol-Myers Squibb) and
its
hydrochloride, sulfate, phosphate salts; and miglitol (Glyset,
Pharmacia/Upjohn);
Anti-glaucoma Agents such as dorzolamide (Cosopt, Merck); timolol; betaxolol
and
its hydrochloride, sulfate, phosphate salts; atenolol; and clorthalidone;
Anti-(Chromatin Modifying Enzymes) such as suberoylanilide hyroxaxamic
acid (Aton/Merck);
Agents for Obesity Management, such as glucagon-like-peptides,
phendimettrazine
-- and its tartrate, hydorochloride, sulfate, phosphate salts; methamphetamine
and its
hydrochloride, sulfate, phosphate salts; and sibutramine (Meridia, Abbott) and
its
hydochloride, sulfate, phosphate salts;
Treatments for Anemia such as epoetin alpha (Epogen, Amgen); epoetin alpha
(Eprex/Procrit, Johnson & Johnson); epoetin alpha (ESPO, Sankyo and Kirin);
and
-- darbepoetin alpha (Aranesp, Amgen); epoetin beta (NeoReconnon, Roche);
epoetin beta
(Epogen, Chugai); GA-EPO (Dynepo, TKT/Aventis); epoetin omega (Elanex/Baxter);
R 744
(Roche); and thrombopoetin (Genetech/Pharmacia);
Treatments for Emesis such as promethazine (Phenergan, Wyeth);
prochlorperazine;
metoclopramide (Reglan, Wyeth); droperidol; haloperidol; dronabinol (Roxane);
ondasetron
-- (Zofran, GlaxoSmithKline); ganisetron (Kytril, Roche); dolasetron (Anzemet,
Aventis);
indisetron (NN-3389, Nisshin Flour/Kyorin); aprepitant (MK-869, Merck);
palonosetron
(Roche/Helsinn/MGI Pharma); lerisetron (FAES); nolpitantium (SR 14033, Sanofi-
Synthelabo); R1124 (Roche); VML 670 (Vemalis, Eli Lilly & Co.); and CP 122721
(Pfizer);
Neutropaenia Treatments such as filgrastim (Neupogen, Amgen); leuldne
-- (Immunex/Schering AG); filgrastim-PEG (Neulasta, Amgen); PT 100 (Point
Therapeutics);
and SB 251353 (GlaxoSmithKline);
Tumor-induced Hypercalcaernia Treatments such as Bonviva (GlaxoSmithKline);
ibandronate (Bondronat, Roche); pamidronate (Aredia, Novartis); zolendronate
(Zometa,
26
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
Novartis); clodronate (Bonefos, generic); incadronate (Bisphonal, Yamanouchi);
calcitonin
(Miacalcitonon, Novartis); minodronate (YM 529/Ono 5920, Yamanouchi/Ono); and
anti-
PTHrP (CAL, Chugai);
Blood Anticoagulants such as Argathroban (GlaxoSinithKline); warfarin
(Coumadin,
duPont); heparin (Fragmin, Pharmacia/Upjohn); heparin (Wyeth-Ayerst);
tirofiban
(Aggrastat, Merck) and its hydrochloride, sulfate, phosphate salts;
dipyridamole (Aggrenox,
Boehringer Ingelheim); anagrelide (Agrylin, Shire US) and its hydrochloride,
sulfate,
phosphate salts; epoprostenol (Flolan, GlaxoSmithKline) and its hyrochloride,
sulfate,
phosphate salts; eptifibatide (Integrilin, COR Therapeutics); clopidogrel
(Plavix, Bristol-
Myers Squibb) and its hydrochloride, sulfate, or phosphate salts; cilostazol
(Pletal,
Pharmacia/Upjohn); abciximab (Reopro, Eli Lilly & Co.); and ticlopidine
(Ticlid, Roche);
Immunsuppressive Agents such as sirolimus (rapannycin, Rapamune , Wyeth-
Ayerst); tacrolimus (Prograf, FK506); and cyclosporins;
Tissue Repair Agents such as Cluysalin (TRAP-508, Orthologic-Chrysalis
Biotechnology);
Anti-psoriasis Agents such as anthralin; vitamin D3; cyclosporine;
methotrexate;
etretinate, salicylic acid; isotretinoin; and corticosteroids;
Anti-acne Agents such as retinoic acid; benzoyl peroxide;sulfur-resorcinol;
azelaic
acid; clendamycin; erythromycin; isotretinoin; tetracycline; minocycline;
Anti-skin parasitic Agents such as permethrin and thiabendazole;
Treatments for Alopecia such as minoxidil and finasteride;
Contraceptives such as medroxyprogesterone; norgestimol; desogestrel;
levonorgestrel; norethindrone; norethindrone; ethynodiol; and ethinyl
estradiol;
Treatments for Smoking Cessation including nicotine; bupropion; and buspirone;
Treatments for Erectile Disfunction such as alprostadil; and Sildenafil;
DNA-alkyltranferase Agonist including temozolornide;
Metalloproteinase Inhibitor such as marimastat;
Agents for management of wrinkles, bladder, prostatic and pelvic floor
disorders such
as botulinum toxin;
Agents for management of uterine fibroids such as pirfenidone, human
interferin-
alpha, GnRH antagonists, Redoxifene, estrogen-receptor 'modulators;
Transferrin Agonist including TransMID (Xenova. Biomedix); Tf-CRM107
(KS Biomedix);
27
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
Interleukin-13 Receptor Agonist such as IL-13-PE38QQR (Neophann);
Nucleic acids such as small interfering RNAs (siRNA) or RNA interference
(RNAi),
particularly, for example siRNAs that interfere with VEGF expression;
and Psychotherapeutic Agents including Anti-anxiety drugs such as
chlordiazepoxide;
diazepam; chlorazepate; flurazepam; halazepam; prazepam; clorazepam;
quarzepam;
alprazolam; lorazepam; orazepam; temazepam; and triazolam; and Anti-psychotic
drugs such
as chlorpromazine; thioridazine; mesoridazine; trifluorperazine; fluphenazine;
loxapine;
molindone; thiothixene; haloperidol; pimozide; and clozapine.
Those of ordinary skill in the art will appreciate that any of the foregoing
disclosed
active agents may be used in combination or mixture in the pharmaceutical
formulations of
the present invention. Such mixtures or combinations may be delivered in a
single
formulation, or may be embodied as different formulations delivered either
simultaneously or
a distinct time points to affect the desired therapeutic outcome.
Additionally, many of the
foregoing agents may have more than one activity or have more than one
therapeutic use,
hence the particular category to which they have been ascribed herein is not
limiting in any
way. Similarly, various biodegradable, biocompatible excipients may be used in
combination
or in mixtures in single or multiple formulations as required for a particular
indication. These
mixtures and combinations of active agents and excipients may be determined
without undue
experimentation by those of ordinary skill in the art in light of this
disclosure.
The formulations of the present invention may be sterilized for use by methods
known
to those of ordinary skill in the art. Autoclaving and e-beam have been used
in informal
studies of several embodiments and have not appeared to have significant
impact. Similarly,
informal stability studies indicate acceptable stability of several
embodiments. Additionally,
reproducilibity between aliquots and lots is very good, with a standard
deviation of less than
five percent or better. Hence, standard pharmaceutical manufacturing
techniques are readily
applied to the technologies described herein.
An example embodiment of the present invention comprises the active agent
dexamethasone and the excipient benzyl benzoate. Dexamethasone is a
glucocorticoid and
typically used in the form of the acetate or disodium phosphate ester.
Glucocorticoids are
adrenocortical steroids suppressing the inflammatory response to a variety of
agents that can
be of mechanical, chemical or immunological nature. Administration of
dexamethasone can
be topical, periocular, systemic (oral) and intravitreal. Doses vary depending
on the condition
treated and on the individual patient response. In ophthalmology,
dexamethasone sodium
28
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
phosphate (Decadron , Merck & Co.) as a 0.1% solution has been widely used
since its
introduction in 1957. The ophthalmic dose depends on the condition treated.
For control of
anterior chamber inflammation, the- topical dose is usually 1 drop, 4 times a
day for up to a
month following surgery (around 0.5 mg per day). For control of posterior
segment
inflammation, periocular injections of 4 mg of dexamethasone, or daily oral
administration
of 0.75 mg to 9 mg of dexamnethasone in divided doses are not uncommon.
Intravitreal
injections of 0.4 mg of dexamethasone have been administered in conjunction
with
antibiotics for the treatment of endophthalmitis.
Benzyl benzoate (CAS 120-51-4, FW 212.3). In the past, the oral administration
of
benzyl benzoate was claimed to be efficacious in the treatment of intestinal,
bronchial, and
urinary ailments, but its use has been superseded by more effective drugs.
Presently, it is
topically applied as a treatment for scabies and pediculosis. Goodman &
Gilman's THE
PHARMACOLOGICAL BASIS OF THERAPEUTICS 1630 (6th ed., 1980); FDA approval, Fed
Reg. 310.545(a)(25)(i). Benzyl benzoate is approved in minor amounts in foods
as a flavoring
(FDA, Title 21, vol. 3, ch I, subch B, part 172(F), 172.515), and as a
component in solvents
for injectable drug formulations (see, e.g., Faslodex and DelestrogenC)).
Benzyl benzoate is a relatively nontoxic liquid which when applied topically
in the
eye results in no damage. Grant, TOXICOLOGY OF THE EYE 185 (2d ed., 1974). Its
oral Ld50 in
humans is estimated to be 0.5 g/kg -5.0 g/kg. Gosselin et al., II CLIN Tox OF
COMMERCIAL
PROD. 137 (4th ed., 1976). In vivo, benzyl benzoate is rapidly hydrolyzed to
benzoic acid and
benzyl alcohol. The benzyl alcohol is subsequently oxidized to benzoic acid,
which is then
conjugated with glucuronic acid and excreted in the urine as benzoylglucuronic
acid. To a
lesser extent, benzoic acid is conjugated with glycine and excreted in the
urine as hippuric
acid. HANDBOOK OF PESTICIDE TOXICOLOGY 1506 (Hayes & Laws, eds., 1991).
Dexamethasone, when mixed with benzyl benzoate, forms a uniform suspension. A
formulation of 25% is easily syringeable. When the suspension is slowly
injected into the
posterior segment of the eye, for example, a uniform spherical deposit
(reservoir) is formed in
the vitreous body. The reservoir maintains its integrity and in vivo
"breakage" has not been
obverved ophthalmoscopically. Dexamethasone is then released slowly into the
vitreous
humor of the posterior segment. Dexamethasone and benzyl benzoate are
eventually
metabolized to byproducts that are excreted in the urine.
Similarly, triamcinolone acetonide (TA) in benzyl benzoate forms a syringeable
suspension that retains its integrity and in vivo. In rabbit studies involving
intraocular
29
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
injection of TA/benzyl benzoate formulations, described below, near zero-order
release of
TA has been observed in vivo for more than one year (data not shown). Smaller
doses result
in more-rapid release profiles, such that the TA is released over a six-month
period (data not
shown). Both Dex and TA formulations may be useful in treating the eye
following cateract
surgery or replacement.
An aspect of the invention provides for a composition comprising an active
agent and
the LSBB excipient useful for the treatment of iris neovascularization from
cataract surgery,
macular edema in central retinal vein occlusion, cellular transplantation (as
in retinal pigment
cell transplantation), cystiod macular edema, psaudophakic cystoid macular
edema, diabetic
macular edema, pre-phthisical ocular hypotomy, proliferative
vitreoretinopathy, proliferative
diabetic retinopathy, exudative age-related macular degeneration, extensive
exudative retinal
detachment (Coat's disease), diabetic retinal edema, diffuse diabetic macular
edema,
ischemic ophthalmopathy, chronic focal immunalogic corneal graft reaction,
neovascular
glaucoma, pars plana vitrectomy (for proliferative diabetic retinopathy), pars
plana
vitrectomy for proliferatve vitreoretinopathy, sympathetic ophthalmia,
intermediate uveitis,
chronic uveitis, intraocular infection such as endophthalmitis, Irvine-Gass
syndrome.
Another embodiment of the invention provides to formulations and uses of the
tocopherols and/or tocotrienols and their esters with the insulins for the
transdermal delivery
of the insulins in the management of diabetes. Tocopherols and/or the
tocotrienols and their
esters possess outstanding capabilities to carry therapeutic agents,
especially moderate
molecular weight proteins such as the insulins, through the skin into the
body. Indeed, it is
contemplated that wide variety of other therapeutic agents (such as: steroids,
NSAIDs,
antibiotics, hormones, growth factors, anti-cancer agents, etc) may be
available for effective
transdermal delivery formulations with the tocopherols and/or tocotrienols and
their esters.
The advantages to bypassing oral drug delivery that allow the enzymatic
transformations of the liver and the digestive processes of the gut (and also
engender gastric
distresses) have inspired research to find alternative methods. A prime
example is insulin
therapy for diabetes. Several tutorials and reviews of the present state of
insulin therapies are:
Owens, 1 Nature Reviews/Drug Discovery 529-540 (2002); Cefalu, 113(6A) Am J
Med 25S-
35S (2002); Nourparvar et al., 25(2) Trends Pharmacol Sci, 86-91 (2004).
Avoidance of daily
multiple painful subcutaneous injections has led to alternative routes such as
buccal/sublingual, rectal, intranasal, pulmonary, and transdermal. Yet no
completely
acceptable alternatives to injection have been established. Most promising are
pulmonary
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
systems (Exubra, Pfizer/Aventis; AERxiDMS, Aradigm/Novo Nordisk) and as
disclosed here
novel transdermal delivery formulations involving the tocopherols and/or
tocotrienols and
their esters as penetrating vehicles for therapeutic agents.
The desirability of simple and painless transdermal delivery of insulin and
other
therapeutic agents has inspired a number of transdermal approaches
(iontophoresis (electrical
charge); phonophoresis (ultrasound); photoenhancement (pulsed laser); heat;
transfermers
(lipid vesicles); and penetrating agents (DMSO, NMP. etc.)) over the years
with incomplete
results. Transdermal delivery is considered to be hindered by the skin's
relatively
impermeability to large hydrophilic polypeptides such as insulin. The present
invention,
however, provides effective levels of insulin delivered in a sustained release
fashion into the
bloodstream when applied as intimate mixtures with a-tocopheryl acetate onto
the skin. In a
mouse model, effective levels of insulin were delivered in a sustained release
fashion into the
bloodstream of a mouse when applied as intimate mixtures with a-tocopheryl
acetate onto the
mouse skin.
Because tocopherols have long been ingredients in sunscreen and cosmetic
formulations, there are numerous references in the literature to the
tocopherols' being applied
to the skin and demonstrations of their migrating through the skin. See e.g.,
Zondlo, 21(Suppl
3) Int J Toxicol, 51-116 (2002). These reports show the ease and safety with
which the
tocopherols can penetrate skin, but none disclose any use of the tocopherols
as penetration
enhancers or carriers of therapeutic agents through the skin into the body.
Indeed, a recent
review of 102 chemical penetration enhancers for transdermal drug delivery did
not mention
the tocopherols or tocotrienols. Karande et al., 102(13) Proc Natl Acad Sci
USA, 4688-93
(2005).
Tocopherol formulations that allow the facile and effective transport of
therapeutic
agents through the skin into the body may employ d, 1, and dl isomers of
alpha, beta, gamma
and delta tocopherols and their esters (formates, acetates, propionates, C4 to
C20 straight and
branched chain aliphatic acid esters, maleates, malonates, fumarates,
succinates,
ascorbates,and nicotinates); d, 1, and dl isomers of alpha, beta, gamma, and
delta tocotrienols
and their esters (formates, acetates, propionates, C4 to C20 straight and
branched chain
aliphatic acid esters, maleates, malonates, fumarates, succinates, ascorbates
and nicotinates).
Another embodiment of the present invention, further related to the
tocopherols,
provides to formulations of 2-acetyloxy benzoic acid and its aliphatic esters
with tocopherols
and tocotrienols and licorice extracts. In particular, this aspect provides
for injectable,
31
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
ingestable or topical formulations employing the tocopherols and/or
tocotrienols and/or
licorice extracts with 2-acetyloxybenzoic acid (2-ABA) and certain of its
aliphatic esters
allow all the well known medicinal benefits of 2-ABA and its aliphatic esters
while
substantially avoiding the gastric toxicities normally associated with the
ingestion of 2-ABA
itself.
Unlike the more recently developed specific COX-2 inhibiting nonsteroidal anti-
inflammatories such as celecoxib, rofecoxib, and the like, there is the
confidence that decades
of pharmaceutical experience with 2-ABA have well defined its benefits and
disadvantages.
The full benefits and problems of the specific COX-2 inhibitors are still
being discovered. In
the case of the "traditional" NSAIDs such as 2-ABA, ibuprofen, naproxen,
ketoprofen,
diclofenac, indimethacin, etc., evidence accumulates on the damage they do to
the stomach
and small bowel. Although the specific COX-2 inhibitors have demonstrated
lower
gastrointestinal problems than 2-ABA, serious cardiovascular problems
associated with
specific COX-2 inhibitors are surfacing. As for 2-ABA, its general analgesic
anti-
inflammatory benefits are legendary; and as the chemistries of both of its COX-
1 and COX-
2 inhibitions are revealed the cardioprotective properties associated with its
COX-1 inhibition
are in striking contrast to the cardiovascular safety problems of the COX-2
only inhibitors.
The reason for 2-ABA's gastrointestinal toxicity has been ascribed to its COX-
1 inhibition.
And indeed the lower order of gastrointestinal problems of celecoxib,
rofecoxib, and the like
is seen to be due to their COX-2 only inhibition. But, interestingly the
normal intestinal
appearances in the COX-1 knockout animals point to more subtle reasons for 2-
ABA's
gastrointestinal toxicity. The concomitant inhibition of both COX-land 2
enzymes may be
the problem.
Whatever the mechanisms for 2-ABA's gastrointestinal toxicity, the well
demonstrated benefits of 2-ABA in other areas of the body are incentives to
seek ways to get
the molecule past the gut without damage. Of course injection or topical
application avoid the
gut, but the major mode of administration is ingestion. Three distinctly
different methods of
lowering the gut irritation of ingested 2-ABA have been reported. The first,
and most
successful, is the discovery in studies in rats and pigs by Rainsford and
Whitehouse reported
in 1980 (10(5) Agents and Actions, 451-56) that the methyl, ethyl, and phenyl
esters of 2-
ABA elicit practically no gastric ulcerogenic activity and yet still have
nearly all the anti-
inflammatory properties of 2-ABA. Surprisingly, the investigation of oral
administrations of
the esters of 2-ABA has not been pursued further. Topical applications of 2-
ABA esters for
32
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
acne control, sunscreen, and placating insect bites have been reported. See
U.S. Patents No.
4,244,948, No. 4,454,122, No. 3,119,739. The second method of reducing 2-ABA
gastric
distress recommends diets rich in tocopherols and/or tocotrienols, resulting
ing about a 30%
to 40% reduction in lesion formation which is not as extensive as that
provided by 2-ABA
esters. See e.g., Jaarin et al., 13(Suppl) Asia Pac J Clin Nutr, 5170 (2004);
Nafeeza et
al., 11(4) Asia Pac J Clin Nutr 309-13 (2002); Sugimoto etal., 45(3) Dig Dis
Sci, 599-605
(2000); Stickel et al, 66(5) Am J Clin Nutr 1218-23 (1997). The third method
of reducing
gastric stress is by the concomitant oral administration of licorice extract
(glycyrrhizin) with
2-ABA. Rainsford & Whitehouse, 21 Life Sciences 371-78 (1977); Dehpour et al.,
46 J
Pharm Pharmacol 148-49 (1994). This gave 66% to 80% reduction in ulceration
compared to
2-ABA alone. Formulations combining 2-ABA or its esters, the tocopherols (or
their acetates)
and/or tocotrienols (or their acetates), and licorice extracts all together
have not been tried.
Treatment of inflammatory conditions of the eye or joints by direct injection
avoids
gastric distress and the inefficient systemic exposure of the ingestion route.
Ingestion in
humans of the commonly prescribe dosages of 2-ABA (0.650 ¨ 1.3 g) leads to
combined 2-
ABAJ2-hydroxy benzoic acid (2-HBA) levels in the plasma of about 20-100 pg/ml.
Kralinger et al., 35 Ophthalmic Res 107 (2003). Studies in rabbit eyes
indicate that at these
plasma levels the concentration of 2-ABA/2-HBA in the vitreous is in the range
of 5-10
jig/mi. The 2-ABA level is much lower than 2-HBA since within 30 minutes in
the plasma
about 97% of the 2-ABA is hydrolyzed to 2-HBA. Once remaining 2-ABA reaches
the
vitreous its rate of hydrolysis in that environment is greatly reduced. There
an initial level of
41.t.g/m1 is halved in 1.5 ¨ 2 hours. the half-life of 2-HBA is not well
defined since its initial
concentration is increased by the conversion of 2-ABA to 2-HBA; but the half
life is
probably twice that of 2-ABA. Valeri et al., 6(3) Lens & Eye Toxicity Res 465-
75 (1989).
This highlights another advantage of direct injection over oral (systemic)
administration:
injection avoids the substantial loss of the acetyl group in the hydrolysis of
2-ABA before it
reaches its target. It has been shown that the major method of 2-ABA's anti-
inflammatory
action is its ability deactivate the COX 1&2 enzymes by irreversibly inserting
its acetyl group
into these enzymes. Roth & Majerus, 56 J Clin Invest 624-32 (1975). The ID50
for this
reaction in the eye has been determined to be in the range of 0.9 ¨ 9.0
jig/mi. Higgs et al,
6(Suppl) Agents & Actions 167-75 (1979). Kahler et al., 262(3) Eur J Pharmacol
261-269
(1994).
33
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
One example of an injectable sustained release (ISR) 2-ABA formulation in the
eye is
the injection of a 1.0 ml tamponade of silicone oil containing 1.67 mg into
rabbit eye vitreous
chamber. Only 2-HBA was measured in the study, which observed an initial burst
of 640
1..tg/m1 within 6 hours. 2-HBA decreased to 201.tg/m1 in 20 hours and 51.tg/m1
after 120 hours.
Kralinger et al., 21(5) Retina 513-20 (2001). The use of the ethyl ester of 2-
ABA in ISR
formulations should give longer half lives (longer sustained deliveries) than
2-ABA since the
ester is more hydrophobic. Also, the incorporation of 2-ABA esters or 2-ABA
into
hydrophobic excipients such as the tocopherols (or their acetates) or the
tocotrienols (or their
acetates) should lead to longer sustained deliveries.
A study of the distribution of 2-ABA and 2-HBA in the blood and synovial fluid
(human knee) from ingested 650 mg doses of 2-ABA showed the maximum plasma
levels of
3.3 [tg/m1 2-ABA in 7.7 minutes and 23 [tg/m1 2-HBA in 10.9 minutes. Maximum
synovial
fluid levels were 2.5 ps/m1 2-ABA in 19.4 minutes and 14.5 pg/m1 2-HBA in 21.9
minutes.
Soren, 6(1) Scand J Rheumatol 17-22 (1977). The 2-ABA was gone in the blood in
75
minutes and gone in the synovial fluid in 2.3 to 2.4 hours. A study of intra-
articular injections
of 20 lighnl 2-ABA in the 33 ml of synovial fluid in the adult human knee also
revealed that
the average half life of combined 2-ABAJ2-HBA was 2.4 hours. Owen et al., 38
Br J din
Pharmac 347-55 (1994); Wallis et al., 28 Arthritis Rheum 441-49 (1985).
In addition to the references noted above relating to anti-inflammation
therapies
involving topical applications of 2-ABA ester formulations, there are the
references referring
to 2-ABA esters (U.S. Patent No. 3,119,739, U.S. Patent Application Pub. No.
2002-
0013300) or 2-ABA (U.S. Patent No. 4,126,681) as analgesics for skin
irritations and wound
healing. Other reports, however, reveal poor results with topically applied 2-
ABA to relieve
pain from insect bites (Balit et al., 41(6) Toxicol Clin Toxicol 801-08
(2003)) or allergic
reactions (Thomsen et al., 82 Acta Derm Venereal 30-35 (2002)). Better results
were found
on dermal applications of chloroform solutions of 2-ABA (Kochar et al., 47(4)
J Assoc
Physicians India 337-40 (1999)) or slurries of 2-ABA in a commercial skin
moisturizer
(Balakrishnan et al., 40(8) Int J Dermatol 535-38 (2002)) to alleviate the
pain of acute
herpetic neuralgia. It is important to note that most of these reported
formulations contained
water. Thus, unless these formulations were used immediately after their
preparation it is
very likely significant hydrolysis of the 2-ABAs or their esters removed the
acetyl group to
34
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
give the less potent 2-HBA derivatives. There is the need for non-aqueous or
non-alcoholic
penetrating excipients in topical 2-ABA and 2-ABA ester formulations for
useful shelf life.
Hence, in an embodiment of the invention the components used in the
formulations
are selected from the following two groups:
Group I: 2-acetyloxy benzoic acid, methyl 2-acetyloxy benzoate, ethyl 2-
acetyloxy benzoate, n-propyl 2-actyloxy benzoate, isopropyl 2-acetyloxy
benzoate, n-
butyl 2-acetyloxy benzoate, isobutyl 2-acetyloxy benzoate.
Group d, 1 and dl isomers of alpha, beta, gamma and delta tocopherols and
their acetate esters; d, 1 and dl isomers of alpha, beta, gamma, and delta
cotrienols and
their acetate esters; all along with licorice extracts or deglycyrrhized
licorice extracts.
Thus, one aspect of this invention involves novel mixtures of compounds
selected
from group I with compounds selected from group II to give formulations for
oral
administration having essentially all the beneficial therapeutic properties of
2-ABA but with
much less to none of the gastric stress associated with 2-ABA. These novel
formulations for
ingestion have the general compositions of 350 pts/wt 2-ABA or 400 to 500
pts/wt of 2-ABA
esters mixed with 40 to 400 pts/wt tocopherols or their acetates plus 35 to
110 pts/wt
tocotrienols or their acetates plus 400 to 1400 pts/wt licorice extract or
degglycerrhized
licorice extract. A convenient source containing mixture of tocopherols and
tocotrienols is
either palm seed oil extract (Carotech Inc. among many suppliers) or rice bran
oil extract
(Eastman Chemicals, among many other suppliers). There is some evidence that
the palm
seed source is preferred because it has a higher delta tocotrienol content.
Theriault et al.,
32(5) Clin Biochem 309-19 (1999); Yap et al., 53(1) J Pharm Pharmacol 67-71
(2001).
An example, but non-limiting, formulation would be: 350 mg 2-ABA (or 400 mg
ethyl 2-ABA); 200 mg tocopherol/tocotrienol (palm seed oil extract); and 125
mg licorice
extract. Such a formulation might be conveniently contained in a gel capsule
with one to
eight capsules/day being ingested as needed to alleviate inflammatory
conditions throughout
the human or animal body.
Another aspect of this invention involves novel sustained release mixtures of
2-ABA
or 2-ABA esters with tocopherol or tocopherol acetate for intra-ocular or
intra-articular
injections as therapies for inflammatory conditions of the eye or joints of
animals or humans.
The general range of amounts of these components in the formulations is 5 to
95 pts/wt 2-
ABA esters or micronized 2-ABA and 95 pts/wt to 5 pts/wt tocopherol or its
acetate. An
example, but non-limiting, formulation would be: 250 pts/wt ethyl 2-ABA or
micronized 2-
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
ABA; 400 pts/wt a-dl or d-tocopherol acetate. This formulation is amenable to
injection
through 20 gauge to 30 gauge needles in 10 mg to 100 mg aliquots into the
vitreous chamber
of the eye to provide sustained release of therapeutic levels of 2-ABA or its
ester for periods
of 10 days to one year. Similarly 10 mg to 3000 mg of these formulations could
be injected
into the synovial chambers of human or animal joints to provide anti-
inflammatory therapy
for periods of ten days to one year.
A further aspect of this invention involves novel formulations of 5 pts/wt to
95
pts/wt 2-ABA or its esters with 95 pts/wt to 5 pts/wt tocopherols, tocopherol
acetates and/or
tocotrienols, tocotrienol acetates for the topical applications to penetrate
the skin of humans
or animals to alleviate inflammation and pain in the skin or joints. Again, a
convenient source
of both the tocopherols and tocotrienols would be palm seed oil or rice bran
oil extracts. A
specific non-limiting formulation would be: 60 pts/wt ethyl 2-ABA or
micronized 2-ABA; 40
pts/wt palm seed oil extract.
Without further elaboration, one skilled in the art having the benefit of the
preceding
description can utilize the present invention to the fullest extent. The
following examples are
illustrative only and do not limit the remainder of the disclosure in any way.
EXAMPLES
Example 1. Preparation of a Poly(1,3-propanediol carbonate) I from 1,3-
propanediol at 65 C
and 96 hours.
To 23.6 g (0.2 mole) diethyl carbonate (b.p. 128 C) was added 15.2 g (0.2
mole) 1,3-
propariediol containing 0.05 g (1.25 mmole) of metallic Na to give two liquid
phases. These
reactants were placed in an open container in a 65 C oven and were shaken
occasionally.
After 12 hours, the reactants were a homogeneous solution weighing 38.0 g. The
theoretical
weight for the loss of 0.4 moles (18.4 g) of ethanol in a complete reaction
would be 20.4g.
The heating and occasional shaking were continued to give 27.0 g at 24 hours,
23.2 g at 48
hours, 21.4 g at 72 hours, and 17.4 g at 96 hours. The product oil was washed
with 15 ml 5%
aqueous acetic acid to two phases. The top phase was the water soluble phase.
The 10.5 ml
bottom phase was washed with 15 ml water to give 7.5 ml of a poly(1,3-
propylene glycol
carbonate) oligomer as a water-insoluble oil.
36
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
Example 2. Preparation of Poly(1,3-propanediol carbonate) II from 1,3-
propanediol
at 110-150 C and 26 hours.
A mixture of 76 g (1.0 mole) 1,3-propanediol containing 0.1 g metallic Na (2.5
mmole) and 118 g (1.0 mole) diethyl carbonate was heated at 110 C. As soon as
the
reactants reached 60 C they formed a homogeneous solution. After heating 8
hours, the
. reactants had lost 48 g (52% of theoretical amount of ethanol). The
temperature was then
raised to 150 C. After 10 hours, the reactants lost another 46 g. A drop of
this product
completely dissolved in water. The resultant 97 g of oil was mixed with 6 g
(0.05 moles)
diethyl carbonate and the resultant solution was heated with occasional
stirring at 150 C.
After 8 hours, the resultant syrup was found to be partially insoluble in
water.
The product was washed with 100 ml 5% aqueous acetic acid followed by four
washings with 100 ml portions of water to give 46.1 g slightly yellow viscous
oil (46.1/102
= 45% yield).
Example 3. Preparation of a Poly(di-1,2-propylene glycol carbonate) from di-
1,2-
propylene glycol.
To 59.0g (0.5 moles) diethyl carbonate was added 67.0g (0.5 moles) di-1,2-
propylene
glycol which had been reacted with 0.02g Na to form a homogeneous solution.
The reactants
were placed in an open flask at 100 C. After 12 hours, the solution lost 23.4
g (about 50% of
the theoretical 46 g ethanol). After another 15 hours at 150 C the reactants
had lost a total of
53.2 g to give a syrup that was partially insoluble in water. The product was
washed with 100
ml 5% aqueous acetic acid followed by four washing with 100 ml portions of
water to give
25.2 g colorless viscous, water insoluble liquid poly(di-1,2-propylene glycol
carbonate)
oligomer.
Example 4. Preparation of a Poly(tri-1,2-propylene glycol carbonate) from
tri-1,2-propylene glycol.
To 0.1g Na metal -was added t 96.0 g (0.5 mole) tri-1,2-propylene glycol..
After 5
minutes, the Na had reacted leaving a light yellow oil. 59.0 g (0.5 mole)
diethyl carbonate
was added to this liquid and the resultant homogeneous solution was heated to
110 C in an
open flask. After 6 hours, the reactants lost 28.0 g (61% of theory). The
yellow solution was
then heated at 125 C for 8 hours, whereupon the reactants had lost a total of
48 g (104% of
37
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
theory). Another 6.0 g (0.5 moles) diethyl carbonate were added and the
temperature was
raised to 150 C. After 6 hours, the viscous yellow-brown product solution was
washed with
100 ml 5% aqueous acetic acid followed by 4 'washings with 100 ml portions of
water to give
48 g of a viscous orange, water insoluble liquid oligomer.
Example 5. The assay procedure for measuring the release profiles of
dexamethasone or
triamcinolone acetonide from their sustained release formulations (SRF).
The vials for the release studies were labeled and the weight of each vial was
recorded. To each vial was added 3 ¨ 4 grams of 0.9% saline solution and the
weight was
recorded. Then the SRF was injected or placed at the bottom of the vial. The
weight of the
SRF was recorded. An additional amount of 0.9% saline solution was added to a
total of 10
grams of saline. The resulting vial was kept irk an incubator or water bath at
37 C. Samples
were taken periodically to measure the release profile of dexamethasone or
triamcinolone
acetonide using a HPLC instrument. Sampling protocol was carried out according
to the
following procedure: Using a disposable pipette, 8 grams of the saline
solution containing
dexamethasone or triamcinolone acetonide was withdrawn carefully from each
vial. 8 grams
of 0.9% saline solution was then added to each vial. The vials were kept at 37
C after
sampling.
The HPLC analysis was carried out using a Beckman Gold Instrument with an
autosampler. Calibrators with three different concentrations of dexamethasone
or
triamcinolone acetonide in water were prepared. Calibrators and samples were
injected onto a
C18 column (Rainin, 250 x 4.6 mm) containing a guard column (C18, 4.6 mm x 1
cm) and
analyzed, respectively. The column was eluted using a mobile phase of 45% (or
50%)
acetonitrile/water, flow rate 1.0 mL/min, and 7 (or 6) minute run time at an
ambient
temperature. The detector wavelength of 23g nm was used. The dexamethasone or
triamcinolone acetonide (retention times, 6- 4 minutes) concentration of each
sample was
calculated from the standard curve using the software of the Beckman Gold
instrument.
A wash program to clean the HPLC column was set up during the HPLC run. After
every three or four injections, a sample containing 20 (IL of acetonitrile was
injected onto the
column, the column was eluted with a mobile phase of 99% acetonitrile/water,
flow rate 1
mL/min, and a run time 7 minutes. Then the column was equilibrated back to the
original
38
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
mobile phase by injecting 20 pL of acetonitrile, eluting with 45% (or 50%)
acetonitrile/water,
flow rate 1 mL/ min, and a run time 7 minutes.
The sampling times and the active ingredient (for example dexamethasone or
triamcinolone acetonide) concentrations determined from HPLC were recorded and
tabulated.
The percent drug released and the amount of drug released were each calculated
from a
Microsoft Excel software program.
Example 6. Preparation of mixtures of dexamethasone in poly(1,3-propanediol
carbonate) I
and their release profiles.
Preparation of 10% dexamethasone in poly(1,3-propanediol carbonate) I: One
portion
by weight of dexamethasone was mixed with nine portions by weight of the
poly(1,3-
propanediol carbonate) I prepared in Example 1. The resulting suspension was
stirred at an
ambient temperature until a homogeneous mixture formed. The mixture was then
aliquoted
and analyzed for the release profile as shown in FIG. 1.
Preparation of 20% dexamethasone in poly(1,3-propanediol carbonate) I: Two
portions by weight of dexamethasone were mixed with eight portions by weight
of the
poly(1,3-propanediol carbonate) I prepared in Example 1. The resulting
suspension was
stirred at an ambient temperature until a homogeneous mixture formed. The
mixture was then
aliquoted and analyzed for the release profile as shown in FIG. 1.
Example 7. Preparation of mixtures of dexamethasone in poly(1,3-propanediol
carbonate) 11
and their release profiles.
Preparation of 5% dexamethasone in poly(1,3-propanediol carbonate) II: One
portion
by weight of dexamethasone was mixed with nineteen portions by weight of the
poly(1,3-
propanediol carbonate) II prepared in Example 2. The resulting suspension was
stirred at an
ambient temperature until a homogeneous mixture formed. The mixture was then
aliquoted
and analyzed for the release profile as shown in FIG. 2.
Preparation of 10% dexamethasone in poly(1,3-propanediol carbonate) II: One
portion by weight of dexamethasone was mixed with nine portions by weight of
the poly
(1,3-propanediol carbonate) II prepared in Example 2. The resulting suspension
was stirred at
an ambient temperature until a homogeneous mixture formed. The mixture was
then
aliquoted and analyzed for the release profile as shown in FIG. 2.
39
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
Example 8. Preparation of mixtures of dexamethasone in poly(di-1,2-propylene
glycol
carbonate) and their release profiles.
Preparation of 5% dexamethasone in poly(di-1,2-propylene glycol carbonate):
One
portion by weight of dexamethasone was mixed with nineteen portions by weight
of the
poly(di-1,2-propylene glycol carbonate) prepared in Example 3. The resulting
suspension was
stirred at an ambient temperature until a homogeneous mixture formed. The
mixture was then
aliquoted and analyzed for the release profile as shown in FIG 3.
Preparation of 10% dexamethasone in poly(di-1,2-propylene carbonate): One
portion
by weight of dexamethasone was mixed with nine portions by weight of the
poly(di-1,2-
propylene glycol carbonate) prepared in Example 3. The resulting suspension
was stirred at
an ambient temperature until a homogeneous mixture formed. The mixture was
then
aliquoted and analyzed for the release profile as shown in FIG. 3.
Preparation of 20% dexamethasone in poly(di-1,2-propylene glycol carbonate):
Two
portions by weight of dexamethasone were mixed with eight portions by weight
of the
poly(di-1,2-propylene glycol carbonate) prepared in Example 3. The resulting
suspension was
stirred at an ambient temperature until a homogeneous mixture formed. The
mixture was then
aliquoted and analyzed for the release profile as shown in FIG. 3.
Example 9. Preparation of mixtures of dexamethasone in poly(tri-1,2-propylene
glycol
carbonate) and their release profiles.
Preparation of 5% dexamethasone in poly(tri-1,2-propylene glycol carbonate):
One
portion by weight of dexamethasone was mixed with nineteen portions by weight
of the
poly(tri-1,2-propyleneglycol carbonate) prepared in Example 4. The resulting
suspension was
stirred at an ambient temperature until a homogeneous mixture formed. The
mixture was then
aliquoted and analyzed for the release profile as shown in FIG. 4.
Preparation of 10% dexamethasone in poly(tri-1,2-propylene glycol carbonate):
One
portion by weight of dexamethasone was mixed with nine portions by weight of
the
poly(tri-1,2 -propylene glycol) carbonate prepared in Example 4. The resulting
suspension
was stirred at an ambient temperature until the formation of a homogeneous
mixture. The
mixture was then aliquoted and analyzed for release profile as shown in FIG.
4.
Example 10. Preparation of mixtures of dexamethasone in benzyl benzoate and
their
release profiles.
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
In preparing 20% dexamethasone in benzyl benzoate, two portions by weight of
dexamthasone was mixed with eight portions by weight of benzyl benzoate. The
resulting
suspension was stirred at an ambient temperature until a homogeneous mixture
formed. The
mixture was then aliquoted and analyzed for the release profile as shown in
FIG. 5.
Formulations containing 5% and 50% dexamethasone in benzyl benzoate were
prepared under similar conditions to the 20% formulation, with the exception
of the weight
ratio of dexamethasone/benzyl benzoate. Mixtures of 5% and 50% dexamethasone
in benzyl
benzoate were prepared, and the resulting mixtures were aliquoted and small
portions were
analyzed for the release profiles as shown in FIG. 5.
Dexamethasone in benzyl benzoate forms a uniform suspension. A formulation
of 25% is easily syringeable. As the suspension is slowly injected into the
eye's posterior
segment, a uniform spherical deposit (reservoir) is formed in the vitreous
body.
Dexamethasone is then released slowly into the vitreous humor of the posterior
segment.
Dexamethasone and benzyl benzoate are eventually metabolized to byproducts to
be excreted
in the urine.
Example 12. Preparation of mixtures of dexamethasone in diethylene glycol
dibenzoate and
their release profiles.
Ten percent dexamethasone in diethylene glycol dibenzoate was prepared by
mixing
one portion by weight of dexamethosone (Dex) with nine portions by weight of
diethylene
glycol dibenzoate. The resulting suspension was stirred at an ambient
temperature until a
homogeneous mixture formed. The mixture was then aliquoted and analyzed for
the release
profile as shown in FIG. 6.
Using conditions similar to that of the 10% Dex/diethylene glycol dibenzoate
preparation, with the exception of the weight ratios, mixtures of 5% and 25%
Dex/diethylene
glycol dibenzoate formulations were prepared. The resulting mixtures were
aliquoted and
small portions analyzed for the release profiles as described previously. The
resulting release
profiles are shown in FIG. 6.
Example 13. Preparation of mixtures of triamcinolone acetonide in diethylene
glycol
dibenzoate and their release profiles.
Preparations of 5%, 10% and 25% triamcinolone acetonide in diethylene glycol
dibenzoate were prepared as follows: a 0.5, 1.0, or 2.5 portion by weight of
triamcinolone
41
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
acetonide was mixed with a 9.5, 9.0 or 7.5 portion by weight, respectively, of
diethylene
glycol dibenzoate. The resulting suspension was stirred at an ambient
temperature until a
homogeneous mixture formed. The mixture was then aliquoted and analyzed for
the release
profile as described previously. The resulting release profiles are shown in
FIG. 7.
Example 14. Preparation of mixtures of dexamethasone in d-tocopherol or d,l-
tocopherol
acetate and their release profiles.
For the preparation of 10% Dex in d-tocopherol, one portion by weight of Dex
was
mixed with nine portions by weight of d-tocopherol. The resulting suspension
was stirred at
an ambient temperature until a homologous mixture formed. The mixture was then
aliquoted
and analyzed for release profile as shown in FIG. 8.
For the preparation of 20% Dex in d-tocopherol, two portions by weight of Dex
was
mixed with eight portions by weight of d-tocopherol. The resulting suspension
was stirred at
an ambient temperature until the formation of a homologous mixture. The
mixture was then
aliquoted and analyzed for release profile as shown in FIG. 8.
For the preparation of 50% Dex in dl-tocopherol acetate, five portions by
weight of
Dex were mixed with five portions by weight of dl-tocopherol acetate. The
resulting
suspension was stirred at ambient temperature until a homologous mixture
formed. The
mixture was then aliquoted and analyzed for the release profile as shown in
FIG. 8.
Example 15. Manufacturing of a solid drug delivery system with dexamethasone
and
diethylene glycol dibenzoate and its release profile.
Dexamethasone powder and diethylene glycol dibenzoate by weight were mixed
thoroughly by mortar and pestle. The mixture was placed into a Parr pellet
press of 2 mm
diameter to form a solid pellet at 25 C suitable for an implant. The newly
formed pellet was
then weighed in a microbalance before testing for in vitro kinetics as shown
in FIG. 9.
Example 16. Manufacturing of a solid drug delivery system with dexamethasone
and benzyl
benzoate and its release profile.
Dexamethasone powder and benzyl benzoate by weight were mixed thoroughly by
mortar and pestle. The mixture was then placed into a 2 mm diameter Parr
pellet press to
form a pellet at 25 C suitable for an implant. The formed pellet was weighed
and recorded in
a microbalance before testing for in vitro kinetics as shown in FIG. 10.
42
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
Example 17. Manufacturing of a solid drug delivery system with dexamethasone
and
tocopheryl succinate and its release profile.
Dexamethasone powder and tocopheryl succinate powder were thoroughly mixed at
a
ratio of 50/50 by weight. The well-mixed powder was filled into a single
barrel extruder and
heated for 1 hour at 65 C before extruding through a 1 mm orifice.
Micropellets of varying
sizes suitable for implants were cut from the extruded filaments for in vitro
kinetic testing as
shown in FIG. 11.
Example 18. Combination formulations.
Combination with two or more drugs conveniently formulated with an excipient
such
as benzyl benzoate provides for sustained and controlled release of the active
agents. The
variables of volume, concentration and percentages of the ingredients are
factors influencing
duration and therapeutic concentration of the drug(s) released. As an example,
in a 20% (wt)
formulation of a 1:1 dexamethasone:ciprofloxacin in benzyl benzoate, the
release profile of
the two drug is similar and the duration is about twenty-eight to thirty-five
days. The release
profile of the two drugs is shown in FIG. 12 A.
Another useful composition comprises dexamethasone and ciproloxin at a ratio
of 3:1
dexamethasone:ciprofloxin. The duration of release of each drug is prolonged
significantly,
to about sixty days for dexamethasone and longer for ciprofloxin, as shown in
FIG. 12 B.
Example 19. Pharmacokinetics and metabolism of injected formulation comprising
Dex.
To examine the in vivo release of dexamethasone in vivo, a composition of 25%
dexamethasone by weight in benzyl benzoate (DB) was used: 25 ill (low dose)
contained 6
mg dexamethasone, 50 p.1 (high dose) contained 12 mg dexamethasone. Benzyl
benzoate
served as placebo.
The in vivo release of the DB composition was studied in twenty-four rabbits.
Twenty-five i1 of 25% DB was injected into the posterior segment of one eye of
twelve
animals and the contralateral eye received a placebo. Another twelve animals
received 50 ill
of the DB in one eye and 50 tl of the BB placebo in the second eye. Animals
were
euthanized at the appropiate time points and vitreous humor samples were
removed
surgically. Dexamethasone concentration was determined by high pressure liquid
chromatography (HPLC) as described in Example 5.
43
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
For the high dose, the concentration of released dexamethasone was maximal
during
the first week after insertion, with a mean of 5.56 p,g/m1 from Day 7 to Day
90, declining to a
mean level of 1.85 Rg/m1 by Day 90. With the low dose, the mean level of
dexamethason was
2.8 Ag/m1 from Day 7 to Day 60, declining to a mean level of 0.811g/ml. FIG.
13.
Dexamethasone was not detected in any of the control eyes.
Clinically, the 24 animals receiving the placebo or low or high doses of the
DB
showed no evidence of inflammation or infection for the entire study. Animals
were
examined twice weekly both by slit-lamp ophthalmoscopy and fundoscopic
examination. No
evidence of cataracts, vitreous, or retinal abnormality was observed.
Regarding histopathology, three animals were injected with 25 ul of the DB in
one
eye and 25 !Al of the placebo (BB) in the contralateral eye. Another three
animals were
injected with 50 R1 DB in one eye and 50 ul BB in the other eye. They were
followed
clinically weekly and were sacrificed for histopatholoy at 30 days for the low
dose and at 90
days for the high dose. Eyes were fixed in 10% buffered formalin and examined
after H & E
staining. The anterior segment comprising the cornea, anterior chamber, iris,
ciliary body,
and lens were normal. The pigment epithelium, Bruch's membrane, and the
choroids were all
within normal limits. See FIG. 14. There were no obvious differences in the
histopathology
between the treated and control eyes.
To further examine the in vivo anti-inflammatory effect of DB, 25 1,t1 of 25%
DB was
injected into the vitreous of one eye of three New Zealand White (NZW) rabbits
weighing 3 kg - 3.5 kg. Twenty-four hours later, 2.5 mg of bovine serum
albumin (BSA) was
injected into both eyes. The animals were examined daily as well as
ophthalmologically.
Between 10 to 14 days, uveitis with severe fibrinous reaction occurred in the
eye unprotected
by DB. In the eyes injected with DB, little to no inflammation was detected on
examination.
Histopathology, the unprotected eye showed chronic and acute inflammatory
cells in the
uveal tissues as well as in the anterior chamber and the vitreous cavity. In
the protected eye,
there was minimal evidence of inflammation with few round cell infiltration in
the choroids.
The cornea, iris, retina and the choroids were histologically intact. SeeTable
1 below.
44
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
Table 1: Inflammation in NZW
NZW Day 0 Day 14
1
OD BSA/DB* 3+
OS BSA 0-1+
2
OD BSA 3-4+
OS BSA/DB Trace
3
OD BSA/DB 0
OS BSA 4+
BSA: bovine serum albumin; DB: 25% dexamethasone/benzylbenzoate
OD: right eye, OS: left eye; 0-4: severity of posterior segment
inflammation, 4+ being maximum
Another three NZW rabbits were immunized intravenously (IV) with 10 mg of BSA.
Twenty-one days later, following intradermal injection of 0.5 mg BSA/0.1 ml
saline, all
animals demonstrated a strong (+4) Arthus reaction indicating the animals were
systemically
immuned to the BSA. On day thirty, one eye of each animal was injected
intravitreally
with 25 Rl of a 25% DB composition, and 24 hours later 0.5 mg BSA/0.1 ml
normal saline
was injected into both eyes. Severe uveitis developed and persisted in the
ensuing seven to
ten days in the unprotected eye, while the protected eye was judged to be
normal. On day
sixty, repeat skin testing showed that the (+4) Arthus reaction remained
intact, and reinjection
of 0.5 mg BSA/0.1 ml normal saline showed similar protection as observed on
day 30. These
studies imply that DB has immediate and sustained protective effect in the
experimental eye.
When these animals were again challenged with 0.5 mg BSA/ 0.1 ml normal saline
at 90
days, uveitis developed in all eyes, but the inflammation in the protected
(DB) eye appeared
to be less severe. See Table 2 below. Protection against inflammation with 25
R1 of DB lasted
for sixty days. At ninety days, there may have been an insufficient
therapeutic level of
Dexamethasone in the eye.
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
Table 2: Inflammation in protected and unprotected NZW eyes.
NZW Day 0 Day 14 Day 30 Day 60 Day 90
1
OD BSA 3-4+ 3-4+ 3-4+
OS BSA/DB* 0 0 _ 2-3+
2
OD BSA 4+ 3-4+ 3+
OS BSA/DB Trace 0+ 2-3+
3
OD BSA 4+ 4+ 4+
OS BSA/DB 0-1+ 0 2-4+
BSA: bovine serum albumin; DB: 25% dexamethasone/benzylbenzoate
OD: right eye, OS: left eye; 0-4: severity of posterior segment
inflammation, 4+ being maximum
Another three NZW rabbits were immunized similarly IV with 10 mg BSA. Twenty-
four hours later, one eye of each animal was injected with 50 l of 25% DB. At
three months
(90 days), intradermal skin testing evoked a +4 reaction. One week later, 0.5
mg BSA/0.1 ml
normal saline was injected in both eyes of each animal. The protected eye
(injected with 50
1,t1 25% DB) showed little to no clinical uveitis when compared to the
contralateral
unprotected eye. This indicates that chronic sustained release of
Dexamethasone was able to
protect the eye up to three months when challenged locally with BSA. See Table
3 below.
Table 3: Sustained protection in protected NZW eyes.
NZW Day 0 Day 90
1
OD BSA/DB* 0-1+
OS BSA 4+
_ 2
OD BSA/DB 0+
OS BSA 3-4+
3
OD BSA/DB 0-1+
OS BSA 4+
BSA: bovine serum albumin; DB: 25% dexamethasone/benzylbenzoate
OD: right eye, OS: left eye; 0-4: severity of posterior segment
inflammation, 4+ being maximum
46
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
Example 20.. Pharmacokinetics and metabolism of injected formulation
comprising TA.
A composition of 25% TA (Triamcinolone Acetonide) by weight in benzyl benzoate
(TA/B) was used: 25 pl containing 7.0 mg TA and 50 .1 containing 14 mg TA.
Benzyl
benzoate (BB) served as placebo.
The in vivo release of the TA was studied in twenty-seven rabbits. Twenty-five
pi
(25 1) of the composition was injected into the posterior segment of one eye
of twelve
animals and the contralateral eye received 25 pl of BB. Another twelve animals
received 50
p1 of the same composition into posterior segment of one eye and 50 pi BB into
the second
eye. Animals were euthanized at the appropriate time points (each time point
n=3) and
vitreous humor samples were removed surgically for TA concentration by high-
pressure
liquid chromatography (HPLC) as described in Example 5. The mean vitreous
concentration
TA for the 50 ii TA/B at twenty-four hours was 3.25 jig/m1; at 1 month 2.45
jig/ml; at three
months 1.45 jig/m1; and at six months 1.56 jig/mi. The mean vitreous TA level
over the 6
month period was 2.17 jig/mi. The mean vitreous concentration of TA of the 25
jil TA/B
animals was 1.78 jig/m1 at twenty-four hours; 1.31 jig/ml at one week; 0.81
jig/ml at one
month; 0.4 jig/ml at three months; and 0.36 g/m1 at six months, with a mean
of 0.93 jig/ml
over a six month period. TA was not detected in any of the control eyes. See
FIG. 15. For the
pl dose, near zero-order release was been observed in vivo for 270 days (data
not shown).
For the50 pi dose, near zero-order release has been observed in vivo for 365
days (data not
20 shown).
Clinically, the twenty-seven animals receiving the BB placebo showed no
evidence of
inflammation or infection for the entire study. Animals were examined twice
weekly both by
slit-lamp ophthalmoscopy and fundoscopic examination. No evidence of
cataracts, vitreous or
retinal abnormality was seen.
25 Regarding histopathology, six animals were injected with 50 pi of 25%
TA/B in the
right eye and 50 pl of BB in the other eye. They were followed clinically
weekly and were
sacrificed for histopathology at 180 days. Eyes were fixed in 10% buffered
formalin and
examined after H & E staining. The anterior segment comprising the cornea,
anterior
chamber, iris, ciliary body and lens was normal. Histopathology of the
posterior segment
(including the vitreous, retina, photoreceptors cells, pigment epithelium,
Bruch's membrane
and the choroids) was within normal limits. There were no obvious differences
in the
histopathology between the treated and the control eyes.
47
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
Example 21. Solid implant comprising Dex.
The levels of dexamethasone released from a solid implant was studied in the
anterior
chamber of a NZW rabbit. A mixture of 50:50 dexamethasone (Upjohn) and dl-
alpha
tocopherol succinate (Sigma) was extruded through an aperature of 790 uM mm at
25 C. One
(1) mgm of this extruded mixture was surgically placed in the right anterior
chamber of a 4
kg NZW female rabbit. Sampling of the aqueous humor from the anterior chamber
(AC) for
HPLC dexamethasone analysis was performed in accordance with the above
example.
Therapeutic sustained release levels of dexamethasone were observed. See FIG
16.
Clinically, the animal's eye was completely quiescent and the composition was
judged to be
biocompatible.
Example 22. Sustained release of dexamethasone/dl-alpha tocopherol succinate
coating of
stainless steel surface and cardiac stents.
A mixture of 2:8:1 (-wt) of dexamethasone:acetone:tocopherol succinate coating
was
applied to two stainless steel tubing surfaces and two commercial cardiac
stents. Coating was
achieved by dipping and oven drying. Elution of dexamethasone for HPLC
analysis was done
in a 20 ml distilled water vial and exchange of 75% of the total volume took
place per period
of assay. See FIG. 17. Tocopherol succinate has been demonstrated to be an
effective coating
medium on steel surfaces for controlled drug release. The application of this
methodology
could be extended to various materials and surfaces including wood, glass,
various metals,
rubber, synthetic surfaces such as teflon, plastics, polyethylene tubings and
the like.
Example 23. Formulations comprising cyclosporine in tocopherol succinate.
To study the in vitro release of 25:75 dl-alpha tocopherol:Cyclosporin A,
cyclosporin
was mixed with tocopherol succinate and extruded at 25 C through an aperature
of 790 [M.
One mg (1 mg) of the material was placed in 10 ml distilled water vial and
aliquots were
sampled for dissolution as described above. See FIG. 18. Prolonged sustained
release in a
linear fashion was observed for about 272 days.
To study the in vivo release profile, 0.75 mg of the 25:75 tocopherol
succinate:cyclosporin was implanted surgically in the right anterior chamber
(AC) of the 4.0
kg NZW female rabbit. The AC was tapped at the above time-points for HPLC
determination
of CsA in the aqueous humor. See FIG. 19. Additionally, 5.0 mg of 25:75
tocopherol
succinate:cyclosporine was implanted surgically into the left posterior
segment (PS) of a 4 kg
48
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
NZW female rabbit eye. The vitreous humor in the PS was tapped at the above
time-point for
CsA HPLC analysis. See FIG. 20.
In another in vivo release study, 30 rag (3 x 10 mg) of a 25:75 tocopherol
succinate:cyclosporin formulation was extruded through a 1 mm aperature. The
segments
were implanted in the peritoneal cavity of an adult male Sprague-Dawley rat
with a trocar
through a 3 mm incision after local 0.5% lidocaine infiltration. Cardiac
puncture was
performed for blood CsA LCMSMS analysis. See FIG. 21.
Implants of cyclosporin:tocopherol succinate were injected by needle trocar in
various
organs in Sprague-Dawley rats to determine cyclosporin distribution. More
specifically,
extruded 20:80 tocopherol succinate:cyclospcwin of various weights were
implanted. After
sacrifice and harvest, all tissues were dried in a tissue concentrator for 48
hours, crushed and
soaked in 1 ml of Me0H containing lOng/m1 CsD. Analysis were performed with
Mass Spec
Liquid Chromatography. CsA was observed as indicated below in Table4 and Table
5.
Abbreviations: ant anterior, post posterior, hem hemisphere.
49
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
Table 4: Cyclosporin distribution in rat liver and brain.
Liver #1 Upper Lobe, Sacrificed Day 5, 2 mg 80% CsA in toccipherol
succinate was implanted into the ri:ht third of the middle lobe
Upper lobe mg dried tissue ng/ml CsA ng/mg CsA
right third 71.4. mg 2540 35.6
middle third 119.4 191 1.6
left third 88.4 184 2.1
middle lobe
right third* 83.3 2360 28.3
left third 88 878 10
left third 49.2 2620 53.2
blood na 0 na
Observation: CsA distribution was detected in both upper and middle
lobes when implant was implanted in the middle lobe.*
Liver #2 Lower Lobe, Sacrifice 24 hours, 2 mg of implant injected.
right fifth 99.3 254 2.6
right middle 59.6 144 2.4
fifth
Implant* 138.8 2420
left middle 77.5 1710 22
fifth
left fifth 53.5 278 5.2
Observation: Sacrifice at 24 hours showed much higher
concentration in the section of the liver containing the implant.
Brain #1, Sacrifice 24 hours, 1 mg of the formulation was implanted.
left ant hem 47.2 72.1 15.3
left post hem 79.3 180 2.3
right ant hem* 52.7 1190 22.6
right post hem 60.8 385 6.3
blood na 0 na
Observation: CsA distribution was noted in both hemispheres even
though the implant was placed in the right ant hem.*
Brain #2, 1 mg formulation implanted in right ant hem.*
left ant hem 42.2 478 11.3
left post hem 68.6 127 1.9
right ant hem* 73.9 401 5.4
right post hem 113.7 96 0.8
blood na 0.29 na
Observation: Similar to brain # 1, the left ant hem showed much
higher concentration.
*Site of implantation.
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
Table 5: Cyclosporin distribution in rat spleen and kidney.
Spleen, sections right to left, 1 mg implant in section #7.*
mg dried tissue ng/ml CsA ng/mg CsA
section #1 10.3 217 21.1
section #2 16.2 72.5 4.5
section #3 12.9 17.7 1.4
section #4 24.9 62 2.5
section #5 22.5 72.9 3.2
section #6 26.8 101 3.8
section #7* 29 1800 62
blood na 0 na
Observation: Distribution appears higher at the opposite pole of the
spleen.
Kidney, 075 mg implant in lower third.
upper third 156.8 314 2
middle 85.5 333 3.9
lower third* 106.1 165 1.6
Observation: CsA distribution throughout kidney.
* site of implantation.
Example 23. Transdermal delivery of insulin.
The comparinson of injected versus transdermal delivery of several formulation
of
insulin was studied in a mouse model. One mg of porcine insulin was injected
IP
(intraperitoneal) into a mouse. A precipitous drop in glucose level was found
within one-half
hour and developed into hypoglycemia after one hour. Hypoglycemia persisted
below
perceptible levels and the animals never recovered. One mg of porcine insulin
was mixed
with 0.1 ml of tocopherol acetate and injected IP, perceptible drop in glucose
level was seen
up to 3 hours and the animal remained hypoglycemic and did not recover. rp
glucose infusion
did not reverse the hypoglycemia. One mg of porcine insulin mixed with 0.1 ml
of tocopherol
acetate was applied topically on the skin of a shaved mouse. Slow decline of
glucose level
was seen with the lowest level determined at 5.5 hours. Return towards pre-
treatment levels
was seen at 24 hour and 48 hour. Tocopherol IP was able to slow the
hypoglycemic effect of
insulin. Transdermal insulin w Topcopherol Ac produced reduction in glucose
levels with
slow recovery to pre-treatment levels after 24-48 hours. Sustained release of
transdermal
administered insulin was observed (data not shown).
Porcine insulin (20 mg) was mixed in 199 mg/ml of tocopheryl acetate and
formed a
paste (or gel) which and was applied to the backs of shaved albino mice as
follows. Mouse #1
was treated with 39.8 mg of insulin/tocopherol acetate paste, equaling 3.6 mg
of insulin;
51
CA 02582096 2007-03-28
WO 2006/039336
PCT/US2005/034822
mouse #2 was treated with 75.2 mg of insulin/tocopherol acetate paste,
equaling 6.9 mg of
insulin. Tail blood glucose levels were determined by Home Diagnostics, Inc.
True Track
smart system at intervals depicted in FIG. 22.A drop in glucose level was seen
as early as
one-half hour after transdermal application followed by sustained depressed
levels for up to
fifteen hours. By twenty-four hours, glucose had returned to pre-treatment
levels followed by
rebound ro hyperglycemic concentrations for the next twenty-four hours.
Sustained release of
transdermal administered insulin has been demonstrated.
Pharmaceutical agents that may be delivered by this platform include
analgesics,
anesthetics, narcotics, angiostatic steroids, anti-inflammatory steroids,
angiogenesis
inhibitors, nonsteroidal anti-inflammatories, anti-infective agents, anti-
fungals, anti-malarials,
anti-tuberculosis agents, anti-virals, alpha androgenergic agonists, beta
adrenergic blocking
agents, carbonic anhydrase inhibitors, mast cell stabilizers, rniotics,
prostaglandins,
antihistamines, antimicrotubule agents, antineoplastic agents, antiapoptotics,
aldose reductase
inhibitors, antihypertensives, antioxidants, growth hormone antagonists,
vitrectomy agents
adenosine receptor antagonists, adenosine delaminate inhibitor, glycosylation
antagonists,
anti-aging peptides, topoisemerase inhibitors, anti-metabolites, alkylating
agents,
antiandrigens, anti-oestogens, oncogene activation inhibitors, telomerase
inhibitors,
antibodies or portions thereof, antisense oligonucleotides, fusion proteins,
luteinizing
hormone releasing hormones agonists, gonadotropin releasing hormone agonists,
tyrosine
kinase inhibitors, epidermal growth factor inhibitors, ribonucleotide
reductase inhibitors,
cytotoxins, IL2 therapeutics, neurotensin antagonists, peripheral sigma
ligands, endothelin
ETA/receptor antagonists, antihyperglycemics, anti-glaucoma agents, anti-
chromatin
modifying enzymes, obesity management agents, anemia therapeutics, emesis
therapeutics,
neutropaenia therapeutics, tumor-induced hypercalcaemia therapeutics, blood
anticoagulants,
anti-proliferatives, immunosuppressive agents, tissue repair agents, and
psychotherapeutic
agents. Aptamer (Eyetech), and Lucentis (Genentech) and RNA inhibitors.,
insulin, human
insulin, GLP-1, Byetta (exenatide, Amylin).
Modifications of the above described modes for carrying out the invention that
are
obvious to those of ordinary skill in the surgical, pharmaceutical, or related
arts are intended
to be within the scope of the appended claims.
52
